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Abstract 
Advances in immunology have increased the possibility to develop therapeutic cancer vaccines 
(TCV), as a complementary approach to standard treatment. The goal of a successful cancer vaccine 
is to induce a potent long-lasting immune response against the tumour with limited toxicity on 
normal cells. Most tumour cells express tumour-associated antigens (TAA), which can act as targets 
for the immune system. However, most TAAs evade recognition by the immune system to avoid 
auto-immunity, as many TAAs coexist in normal tissues. Commonly expressed TAAs in 
gastrointestinal malignancies are Carcinoembryonic antigen (CEA) and telomerase which both have 
been used as targets in cancer immunotherapy. 
The aim of this thesis was to explore the immunogenicity and safety of a CEA based protein 
and DNA TCV in patients with colorectal cancer (CRC) in the adjuvant setting and telomerase 
vaccination (GV1001) in patients with advanced pancreatic adenocarcinoma (PC). 
A long-term follow-up of CRC patients immunized with recombinant (rCEA) ± Granulocyte-
macrophage colony-stimulating factor (GM-CSF) was conducted. Induction of anti-CEA IgM, 
IgA and IgE antibodies was monitored from 36 months after start of immunization. GM-CSF 
significantly augmented the anti-CEA response for all three classes (p<0.05). A significant 
correlation between survival and high IgA anti-CEA titers was noted (p=0.02). Anti-CEA IgA 
antibodies could lyse CEA positive cells in antibody-dependent cellular cytotoxicity (ADCC) and 
complement-dependent cytotoxicity (CDC) assays. 
The type, severity and duration of side-effects of CEA66-DNA vaccination in combination with 
cyclophosphamide and GM-CSF, was evaluated in 10 CRC patients. CEA66-DNA was delivered by 
a needle-free device system (Biojector). Adverse events (AE) were mild and transient, without any 
grade 3 or 4 AEs. No clinical signs of autoimmunity were seen. 
In an explorative study using CEA66-DNA (producing unglycosylated CEA) and wild type (tetwt)-
CEADNA (producing glycosylated CEA) for immunization in combination with cyclophosphamide 
and GM-CSF immune responses (proliferation assay, ELISPOT, cytokine secretion assay) were 
analyzed in the adjuvant setting of CRC patients. 10 patients received intradermal (i.d.) or 
intramuscular (i.m.) CEA66-DNA by Biojector at weeks 0, 2 and 6 (part 1). 10 patients; (part 2), 
received tetwt-CEADNA 400 µg i.d. by needle followed by electroporation at weeks 0 and 12. Part 
3 (n=6) included patients primed with CEA66-DNA and boosted with tetwt-CEADNA. GM-CSF 
and cyclophosphamide was also included. In total, 16 out of 20 (80%) patients mounted a single 
assay cellular response; 10/10 (100%) in part 1 and in 6/10 (60%) of the patients in part 2 (p=0.025). 
Immune responses were weak but durable. 
We also assessed the safety and immunogenicity in advanced PC patients using a 16 aa telomerase 
peptide (GV1001) for vaccination in combination with GM-CSF and gemcitabine as first line 
treatment. Three different vaccine treatment schedules (groups A, B, C) were used. In groups A and 
B, differing only in the dose of GM-CSF, a total of 67% of the patients showed an induced 
telomerase response. An induced ras (antigenic spreading) specific immune response was noted. All 
responses were weak and transient. A significant decrease in regulatory T cells over time was noted 
in patients in groups A and B. 
In conclusion, durable weak anti-CEA immune responses were seen following rCEA and CEA-
DNA vaccination in CRC patients in the adjuvant setting. Weak and transient anti-telomerase 
responses following peptide vaccination were induced in patients with advanced PC. To develope a 
therapeutic concept of clinical significance measures have to be taken to optimize vaccine strategies. 
Keywords: CEA, hTERT, immunotherapy, cancer vaccine 
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1 THE IMMUNE SYSTEM 
“Den som är väldigt stark måste också vara väldigt snäll” Ur Känner du Pippi Långstrump 
The immune system is crucial to human survival and can be defined as our defence towards 
pathogens. The word immune stems from the Greek word immunitas meaning “liberated or 
excluded from” for example the effects of a specific pathogen. In brief, two groups of the 
immune system coexist and interact constantly; the innate (non-adaptive) and the acquired 
immune system. The innate is quick to respond to pathogens, the acquired is slow but on 
the other hand it gives rise to a specific memory towards the pathogen – rendering a 
quicker and more precise immune response at the next encounter. Thus, the innate immune 
system carries the memory of the species whereas the acquired immune system carries the 
memory of the individual. 
 
The innate responses use phagocytic cells (neutrophils, monocytes and macrophages), cells 
able to release inflammatory mediators (basophils, mast cells, and eosinophils), natural 
killer (NK) cells and natural killer T cells (NKT cells). Besides NK cells, interdigitating 
dentritic cells (DCs) comprise essential links between innate and acquired immunity [1] The 
molecular compartments of innate responses include complement, acute-phase proteins and 
cytokines. Cytokines are proteins made by cells that affect the behaviour of other cells and 
bind to specific receptor on their target cells. Cytokines made by lymphocytes are often 
called interleukins (IL). 
 
Acquired responses involve the proliferation of antigen-specific B and T cells, which 
occurs when the surface receptors of these cells bind to the cognate antigen. Specialized 
antigen-presenting cells (APCs) display the antigen to the major histocompability complex 
(MHC) molecules and cooperate with them in response to the antigen. B cells respond to 
the immunogens by secreting immunoglobins (Ig), the antigen-specific antibodies mainly 
responsible for elimination of extracellular agents. There are two main types of T cells: 
helper T cells (Th) (CD4+) and cytotoxic T cells (CD8+). Although T cells can help the B 
counterpart to make antibodies, they also contribute to the eradication of intracellular 
pathogens by activating macrophages and directly killing infected cells. 
1.1 Antigen presentation to T cells 
The immune system recognizes antigens presented by two types of MHCs, Class I and II. 
In humans, the MHC Class I molecule corresponds to the human leukocyte antigen (HLA)-
A,- B, and C- molecules, and MHC Class II molecules correspond to HLA-D molecules. 
MHC Class I molecules are expressed on all nucleated cells and in general present 8-
11 amino acid-long peptides derived from intracellular proteins digested in the proteasome 
complex. These MHC class I peptide complexes are recognized by CD8+ T cells. If a 
CD8+ cell finds a MHC Class I peptide -complex, with its unique T cell receptor (TCR), it 
undergoes clonal expansion and differentiates into mature CD8+ and memory CD8+ cells. 
Mature CD8+ cells migrate through the body, searching for cells that possess peptide-
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complexes, to which the TCR will bind and destroy. Memory CD8+ cells persist and will 
multiply if they are re-exposed to the same MHC peptide complex again. 
MHC Class II molecules are mainly expressed on APCs, such as dendritic cells (DCs), 
macrophages and activated B cells. These cells engulf proteins and present small peptides, 
in conjunction with MHC Class II to CD4+ T cells. These peptides are longer, usually 13 to 
17 amino acids (or more), and derive from exogenous proteins endocytosed into the cell. If 
a CD4+ cell recognizes such a MHC class II-peptide complex, it will divide and mature 
producing many cytokines and express many surface elements, thereby regulating other 
aspects of the immune system. 
1.2 Activation of naïve T cells 
All types of acquired immune responses are started by the activation of antigen-specific T 
cells and the whole process of activation and differentiation occurs in the immediate 
nursing environment of APCs. Two signals are necessary for the initial activation of naïve 
T cells. The “two signal model” predicts that when an antigen is presented by an MHC 
molecule (signal 1) together with costimulatory molecules (signal 2) expressed by APCs, 
an immune response will be generated [2, 3]. Several costimulatory molecules have been 
described; one important complex is CD28 on T cells binding to B7´s on the APC. 
According to the danger theory, signal 1 in the absence of signal 2 leads to tolerance 
irrespective if the antigen is self or non-self. In the absence of danger signals, the APCs are 
not induced to express costimulatory molecules and the result of such presentation will be 
tolerance rather than activation. Any cell, however, when stressed and in danger, sends 
alarm signals to activate APCs. 
The not-ever present expression of B7´s on APCs ensures that naïve T cells do not 
respond to their specific antigens in the absence of danger. This provides a mechanism for 
peripheral tolerance that prevents naïve T cells with receptor that bind self-antigens from 
being activated and differentiate into auto reactive effector T cells. 
1.3 CD4+ Th1 and Th2 cells 
Towards the end of their proliferation, activated T cells, acquire the capacity to synthesize 
the proteins they need to perform the specialized functions as effector T cells. 
For CD4+ cells these proteins comprise cell-surface molecules and soluble cytokines 
that activate and help other types of cells to participate in the immune response. Because of 
its facilitating functions, CD4+ cells are called T helper (Th) cells. Defining the range of 
behaviour are two types of helper cells called CD4+ Th1 or CD4+ Th2. The main cytokines 
secreted by Th1 cells, IL-2 and INF-γ, promote cytotoxic T cell lymphocytes (CTL) 
generation and activate NK cells. They may also secrete Granulocyte-macrophage colony-
stimulating factor (GM-CSF), which promote a more efficient antigen presentation. The 
main cytokines secreted by Th2 cells, IL-4, IL-5, IL-6 and IL-10, mainly lead to B cell 
differentiation. Thus an immune response biased towards Th1 cells is described as being 
cell-mediated immunity, dominated by CD8+ T effector cells whereas an immune response 
biased towards Th2 cells is dominated by antibodies, described as a component of the 
humoral immunity. 
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1.4 CD8+ T cells 
CD8+ T cells (CTL) are the principle effector cells of the acquired immune response, 
which mediate antigen-specific, MHC-restricted, cytotoxic effects. Antigen-specific CD8+ 
T cells become activated by the TCR-MHC Class I peptide interaction on an APC, together 
with help from activated T cells. The activation of CTL occurs either via direct recognition 
of antigen on the tumor cell, or by presentation of tumor antigens on APC’s (cross 
presentation) (see Section 1.6), which subsequently prime CTL. This leads to clonal 
expansion of antigen-specific CTL that will lyse cells that express the same peptide-MHC 
Class I complex. CTL mediated cytotoxicity is mediated primarily by cytotoxins (perforin, 
granzymes) or via interactions between via interactions between cell surface molecules on 
the CTL (Fas ligand) and the target cell (Fas molecules) [4]. 
1.5 B cells 
Each B cell has a receptor molecule with a single specificity called B cell receptor (BCR) 
or immunoglobulin in its secreted form. Five major Ig classes exist; IgM, IgD, IgG, IgA 
and IgE and these determine the functional activity of the antibody. After developing B 
cells leave the bone marrow, they begin to recirculate between the blood, secondary 
lymphoid tissue and the lymphatic vessels. At this stage the B cells are not fully mature, 
expressing surface IgM and IgD. Naïve B cells (that have not yet met their specific antigen) 
passing through the secondary lymphoid tissue pick up, (via surface immunoglobulins), 
process and present their specific antigens if present there. Upon meeting Th2 cells at the 
same site, the T cell receptor screen the peptides presented by the MHC Class II molecule 
on the B cell. Th2 cells then provide signals that activate the B cell to proliferate and 
differentiate. Some differentiate into plasma cells (the effector cell), which secrete IgM in 
the secreted form rather than the surface-bound form. Other activated B cells differentiates 
and undergo isotype switching and hypermutation, producing other classes of antibodies. 
Cytokines secreted by Th2 cells – IL-4, IL-5 and transforming growth factor-β (TGF-β) 
influence B cells to switch their isotype. Some cells will develop into resting memory B 
cells, capable of a quicker and stronger immune response at the next encounter with the 
antigen. In humans IgG can be further subdivided into four subclasses of human IgG 
(IgG1, IgG2, IgG3 and IgG4), whereas IgA antibodies exist as two subclasses, (IgA1 and 
IgA2). IgG1 and IgG3 are the most potent mediators of antibody dependent cellular 
cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Circulating 
antibodies can bind to antigens on microorganisms or transformed cells and destroy them 
either directly or by ADCC and CDC. Some antigens, notably components of bacterial cell 
walls and capsules, are capable of inducing a rapid antibody response that does not require 
T cell help. 
1.6 Cross-presentation and cross-priming 
As a general rule, exogenous antigens enter the MHC Class II processing pathway and are 
presented to CD4+ T cells. By a process known as cross-presentation exogenous antigens 
are delivered into the MHC Class I processing pathway and presented to CD8+ T cells [5]. 
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Cross-presentation is involved in responses to viral infections, transplanted organs and in 
tumors [5, 6]. TAAs, released by tumor cell or administered as a therapeutic cancer vaccine 
(TCV), are taken up by APCs, which process and present them on APC cell surface 
restricted by their own MHC Class I or II molecules. 
APCs such as DCs can then efficiently prime naïve T cells if they display MHC-
antigen complexes (signal 1) together with costimulatory molecules (signal 2). When an 
immune response is initiated by cross-presentation this is known as a cross-priming of the 
immune response [6]. 
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2 THE INTERACTION BETWEEN THE IMMUNE 
SYSTEM AND CANCER 
2.1 Pioneers of modern oncoimmunology 
Immunotherapy for cancer was initially used over a century ago. In the 1800s German 
physician Paul Ehrlich and the American physician William Bradley Coley proposed that 
vaccination might be used against cancer. Ehrlich delivered the idea of “the magic bullet” 
that would specifically kill malignant cells but failed to demonstrate that weakened cancer 
cells, injected in patients, may generate antitumor immunity [7]. On the other hand, inspired 
by cancer patients who underwent regression following streptococcal fevers, Coley became 
convinced he could use bacteria to kill cancer cells. Coley created a mixture of heat-killed 
bacteria (Coley toxin) in 1896 that mediated potent antitumor effects in patients [8, 9]. One of 
the major hurdles against development of anticancer vaccines, the “self/non-self” 
dichotomy, was later theorized by Frank Macfarlane Burnet in 1949 and in fact hampered 
further development for quite some time [10]. According to this theory, tumors – constituting 
self-tissues – are non-immunogenic and therefore insensitive to immunotherapeutic 
interventions. In 1994, Polly Matzinger however presented a theory that proposed that the 
immune system do not react to non-self (while sparing self) constituents, but would rather 
respond to situations of “danger”, either of exogenous (non-self) or endogenous (self) 
origin i.e. irrespective of the origin [11]. Hence, conditions that have long been thought to be 
immunologically silent, including cancer and trauma, are now thought to be able to activate 
the immune system [12-14]. 
2.2 Tumor immunosurveillance and immunoediting 
The long-standing theory of “immunosurveillance” suggests that cells are constantly 
monitored by an ever-alert immune system and that this surveillance is responsible for 
recognizing and eliminating incipient cancer cells. Accordingly, solid tumors have 
somehow managed to avoid detection by the immune system or have been able to limit the 
extent of immunological killing, thereby evading eradication [15]. 
The developments of carcinogen-induced tumors were assessed in mice deficient for 
various components of the immune system. It was observed that tumors arose more 
frequently and grew more rapidly in immunodeficient mice compared to immunocompetent 
controls. Tumor incidence was, in particular, increased in mice with deficiencies in the 
development or function of CD8+, CD4+ Th1 helper cells, or natural killer (NK) cells. 
Results from this experimental mode demonstrated that both the cellular arms of the innate 
and the acquired immune system contributed significantly to immune surveillance and 
tumor eradication [16, 17]. 
Spontaneous antitumor immunity that eliminates tumors or delays their growth 
involves production of INF-ɣ , as well as the generation of CTLs [18, 19]. Mice deficient in 
interferon (IFN-γ) are more susceptible to induced cancers, as are mice lacking T cells and 
perforin, a key effector protein in T cell cytotoxicity [18, 19]. 
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A number of observations from humans indicate that functional immunosurveillance 
do exist. Patients with ovarian and colon cancer that are heavily infiltrated by CTLs and 
NK have a better prognosis than those who lack such tumor infiltrating lymphocytes (TILs) 
[20-22]. The hypothesis is further strengthened by data that indicate that patients indeed 
develop immune responses to tumor associated antigens [23, 24] (see Section 3.3.1) and also 
by the striking evidence of certain cancers in immunocompromised individuals [25]. 
According to the currently accepted model of immunoediting, neoplasms acquire the 
ability to develop and grow in spite of the immune system in three sequential steps. 
Initially, the growth of cancer is efficiently controlled due to robust tumor-specific immune 
responses (elimination). As the elimination phase is normally unable to completely 
eradicate malignant cells, some of them may acquire alterations that either reduce their 
immunogenicity or increase their resistance to the cytotoxic functions to the immune 
system (equilibrium). Such cells eventually grow uncontrolled (escape), leading to a 
clinically manifest neoplasm [18]. 
Editing refers to the changes that occur spontaneously as a tumor develops under the 
influence of an intact immune system and the understanding of immunoediting 
mechanisms has important implications for cancer immunotherapy in humans, and 
avoiding immune destruction has recently been proposed as an emerging hallmark of 
cancer by Hanahan and Weinberg [15]. 
2.3 The immune response may promote tumorigenesis 
The immune system interacts with tumors throughout their development, and the 
consequences of this interaction have implications for cancer therapy. Some host responses 
may inhibit tumor growth, as discussed previously, but immune responses can also promote 
cancer by provoking chronic inflammation and drive growth, survival and angiogenesis 
(see Figure 1). 
The proinflammatory cytokine tumor necrosis factor (TNF-α), largely produced by 
macrophages and mast cells, is implicated in early cancer development as well as in 
infections. TNF-α promotes cell growth, survival and angiogenesis and the recruitment of 
immune effector cells. The events downstream of TNF-α are not well known, but nuclear 
factor-κB (NF-κβ) family transcription factors appear to be linked to TNF-α and cancer [26]. 
NF-κβ controls the transcription of several proteins involved in cell survival, division, 
growth and is important for the production of many inflammatory cytokines, including 
TNF-α itself. In an animal model for colon cancer, ablation of NF-κβ in immune cells led 
to reduction in tumor growth and ablation in the colonic epithelium decreased tumor 
incidence [27]. For further details, see Figure 1. 
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Figure 1. Complex interactions with the immune system shape tumor development. Chronic 
inflammatory response can be initiated by microbial products or endogenous adjuvants released from 
necrotic cells. These signals activate nuclear factor-κB (NF-κB) in myeloid cells, leading to the 
production of inflammatory cytokines (TNF-α, IL-1β, and IL-6), which in turn activate NF-κB in the 
tumor. Tumor-intrinsic NF-κB activation promotes growth, survival, and proliferation. IL-23 produced by 
myeloid cells can promote the generation of IL-17-secreting T cells, which can further support tumor 
growth. Genotoxic stress in tumor cells can activate NK cell ligands, which can synergize with 
endogenous tumor-specific CD4+ and CD8+ T cells that produce IFN-γ and restrict tumor development. 
Tumors can suppress nascent immune responses through a variety of mechanisms, including 
immunosuppressive cytokines (TGF-β and IL-10) and metabolites [indoleamine 2,3-dioxygenase (IDO)] 
and the expression of negative costimulatory molecules [programmed death ligand 1 (PD-L1)]. Tumors 
can also promote Treg recruitment and differentiation, in part through the recognition of apoptotic cells by 
the MFG-E8 (milk fat globule epidermal growth factor 8) pathway. 
(Reprinted with permission from Copyright Clearance Center. Annual Review of Immunology. Dougan, 
Dranoff [26] Copyright 2014). 
2.4 Tumor immune escape mechanisms 
Tumors themselves might develop several strategies allowing them to escape immune 
surveillance and destruction. Tolerance induction is one of the major mechanisms involved 
and is induced by several steps.  
 Mutation or down-regulation of MHC molecules, particularly MHC Class I, has been 
documented in several tumor types [28]. In many cases, individual HLA alleles are 
selectively lost, but complete MHC Class I loss has been observed in tumors. The most 
common mechanism for total MHC Class I loss is mutations in the β2-microglobulin 
genes. Loss of MHC Class I is an escape mechanisms for CTL recognition. 
 Tumor cells often have altered expression of molecules involved in antigen presentation 
and processing, due to down modulation. Such transporter proteins associated with 
antigen processing (TAP1), low molecular mass-protein 2 (LMP2) and LMP1 
proteasome components, results in suboptimal peptide delivery to MHC Class I [28, 29] 
and impaired antigen presentation. 
 Expression of anti-apoptotic molecules and down-regulation or mutation of pro-
apoptotic molecules renders tumor cells resistant to apoptosis [30]. Due to acquired 
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defects in Fas signal transduction, cancer cells may be resistant to the Fas ligand (FasL)-
mediated cytotoxicity of antitumor T and NK cells. Fas resistance enables the tumor 
cells to express their own FasL, which delivers an apoptotic death signal to activated T 
and NK cells, thereby inhibiting lymphocyte infiltration into FasL-expressing tumor 
nests. 
 Tumor cells themselves or tumor stroma can secrete immune suppressive cytokines such 
as IL-10, TGF-β and vascular endothelial growth factor (VEGF). For example, TGF-β 
inhibits the activation, proliferation and differentiation of T cells, and suppress the 
activity of CTLs and DC, while inducing differentiation of regulatory T cells (Tregs) [31-
33]. Tumors also express the enzyme indoleamine 2, 3-dioxygenase (IDO) which 
prevents proliferation of CD8+ cells and induce apoptosis of CD4+ T cells [34, 35] (see 
Figure 1). 
2.5 Suppressive tumor infiltrating leucocytes 
Evidence suggests that, unlike cells found in lymphoid organs that respond to acute 
infections, immune cells in tumors are dysregulated and functionally impaired and use 
immune-regulatory patterns to generate an immune-suppressive environment. Tumor 
infiltrating leukocytes subsets can play strikingly antagonistic functions [36]. 
The suppressive microenvironment of tumors is further established through the activity 
of myeloid derived suppressor cells (MDSC), activated macrophages, and Tregs [37-40].  
 
MDSCs are described as a population of CD11b+ Gr-1+ cells in mice with the ability to 
suppress CD8+ T cell antitumor activity [41, 42]. GM-CSF is important in driving the 
expansion of these cells [43]. Studies have shown that MDSCs are a heterogeneous 
population of cells consisting of cells of monocytic as well as granulocytic origin [43]. In 
humans, the markers for MDSCs are not clearly defined, but the phenotype resides within a 
population of LIN-HLA-DR-CD33+ cells [43]. 
MDCS`s express high levels of two enzymes called inducible nitric oxidase synthase 
(iNOS) and arginase, leading to depletion of, for T cells, essential nutrients [43, 44]. Arginase 
depletes L-arginine from the tumor environment and induces cell cycle arrest in T cells [45]. 
iNOS leads to increased production of nitric oxide (NO). High levels of NO block specific 
signal transduction in T cells, leading to suppressed production of IL-2 [43, 44]. Other 
mechanisms include sequestration of cysteine, an essential amino acid for T cells and 
secretion of IL-10 which has suppressive properties. The ability to skew the differentiation 
of CD4+ T cells to regulatory cells has also been suggested [46]. Taken together, MDSCs 
exercise many functions that blunt effector T cell responses. 
Tumor associated macrophages (TAM), are divided into two subsets, M1 and M2. 
INF-γ drives the polarization towards M1, IL-4 polarizes macrophages towards M2 
profile[36] promoting tumor evasion [40, 47, 48]. M2-skewed macrophages produce lower levels 
of proinflammatory cytokines, such as IL-1β, TNF-α and IL-12 and higher levels of 
immunosuppressive cytokines, such as IL-10, TGF-β and VEGF. Dysfunctional 
macrophages have an impaired ability to mediate direct lysis of malignant cells in 
comparison to M1-type cells [49].The most frequent TAM phenotype seems to be M2 [36]. 
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Regulatory T cells (Tregs) also infiltrate many tumors [50], their immune suppressive 
profile was established in a series of experiments showing that CD25+ T cell depletion 
improved antitumor immunity in mouse models [51-53]. Characteristics of 
CD4+CD25highFOXp3+ T cells (Tregs) are their anergic state and their capacity to inhibit 
CD8+, T cells, DCs, NK cells, NKT cells and B cells [54]. Tregs constitute 5-10% of human 
CD4+ T cells and have a pivotal role in maintenance of immunologic self-tolerance and 
avoiding auto-immunity [55]. They are subdivided into “natural” Tregs (nTreg) cells. nTreg 
develop in the thymus and act through contact-depending mechanisms, maintaining self-
tolerance and preventing autoimmunity [56], “induced” Treg (iTreg) cells, are induced to 
differentiate in the periphery and mediate suppression by contact-independent mechanisms, 
including production of TGF-β [56, 57]. Tregs also secrete suppressive IL-10 creating an 
environment that blunts effector antitumor responses by CD4+, CD8+ and NK cells and by 
acting as a competitive sink regarding IL-2, due to high affinity for IL-2, in the tumor 
environment [58, 59]. Activated T cells become exquisitely sensitive to the lack of IL-2, 
leading to cell death under conditions of IL-2 deprivation [60].  
The transcription factor FoxP3 is critical for the development of the functional 
characteristics of regulatory T cells [61, 62]. FoxP3-knockout mice, and humans with 
homozygous mutation of FoxP3 (encoded on the X chromosome) develop autoimmune 
syndromes involving multiple organs [57]. An increase of Tregs, both in the periphery and 
within tumors, is seen in human cancer [63, 64] and the presence of these cells correlates with 
poor prognosis in ovarian cancer, breast cancer and hepatocellular carcinoma [50]. 
2.6 Immunosuppressive checkpoints 
Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), is an important immune-
checkpoint receptor that normally prevents excessive and uncontrolled immune responses. 
It is expressed exclusively on T cells where it primarily regulates the amplitude of the early 
stages of T cell activation.  
CTLA-4 counteracts the activity of the T cell co-stimulatory receptor CD28 [57]. CD28 
does not affect T cell activation unless the TCR is first engaged by cognate antigen. Once 
antigen recognition occurs, CD28 signalling strongly amplifies TCR signalling to activate 
T cells. CD 28 and CTLA-4 share identical ligands; CD80 (also known as B7.1) and CD86 
(also known as B7.2). As CTLA-4 has a much higher affinity for both these ligands, it has 
been proposed that it´s expression on the surface of T cells dampens the activation of T 
cells by outcompeting CD28 binding to CD80 and CD86 [57], thereby acting 
immunosuppressive. Even though CTLA-4 is expressed by activated CD8+ effector T cells, 
the major physiological role of CTLA-4 seems to be through distinct effect on two major 
subsets of CD4+ T cells; downmodulation of helper T cell activity and enhancement of the 
immunosuppressive activity of regulatory Tregs [57]. 
In contrast to CTLA-4 the major role of Programmed death 1 (PD1) is to limit the 
activity of T cells in peripheral tissues at the time of an inflammatory response to infection 
and to limit autoimmunity. PD1 thus predominantly regulates effector T cell activity within 
tissue and tumors, whereas CTLA-4 predominantly regulates T cell activation [57]. PD1 is 
highly expressed on Tregs where it may enhance its proliferation in the presence of its ligand 
[57]. PD1 is also expressed on B cells and NK cells – limiting their lytic activity [57]. PD1 is 
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normally transiently induced following immune activation but chronic antigen exposure, 
such as occurs with chronic viral infection or cancer, can lead to high levels of persistent 
PD1 expression, which induces a state of exhaustion or anergy among cognate antigen-
specific T cells [57]. 
The PD1 ligands are commonly upregulated on the tumor cell surface in many human 
cancers [65]. The major PD1 ligand that is expressed is programmed death ligand 1 (PDL1) 
[57]. PDL1 (present or not present) status in tumors has been correlated with poor prognosis, 
better prognosis or without correlation to prognosis, probably due to differences in 
analyses, tumor types and stages [57]. 
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3 IMMUNOTHERAPY IN CANCER 
3.1 Background 
General Components 
Immunotherapy against cancers includes active, passive or immunomodulatory strategies. 
While passive immunotherapy administers exogenously produced components such as 
antibodies, active immunotherapies augment the ability of the patients own immune system 
to mount an immune response able to recognize and eliminate malignant cells. 
Immunomodulatory agents are not targeted at specific antigens but enhance general 
immune responsiveness. 
3.2 Passive immunotherapy 
Impressive clinical responses to monoclonal antibodies (mAb) therapy have already been 
achieved and several are part of routine treatment, both in the adjuvant and palliative 
setting. Several murine, chimeric as well as humanized mAbs have been approved. Of 
these, no less than 14 mAbs, including naked reagents as well as mAbs coupled to 
antibiotics or radioactive isotopes, are nowadays authorized for use in cancer patients [66, 67].  
mAbs that potentially exert antineoplastic effects belong to one of six classes [68]:  
1) mAbs that target cancer cell-intrinsic prosurvival signal transduction cascades, e.g. 
cetuximab (Cet) targeting epidermal growth factor receptor (EGFR) (in CRC) 
2) mAbs that interrupt thropic interaction between malignant cells and stroma, e.g. 
bevacizumab (Bev) targeting VEGF (in several adenocarcinomas)  
3) mAbs that recognize antigens expressed on surface of tumor cells and initiate ADCC as 
well as CDC, e.g. Rituximab targeting CD20 (in lymphoma) 
4) Bispecific mAbs, who can bind two antigenic targets, while retaining ability to exert 
immune effector functions e.g. catumaxomab, an anti CD3 and anti-epithelial cell-
adhesion molecule (EpCAM) mAb (in EpCAM+ tumors) 
5) Immunoconjugates e.g 90Y-ibritumomab (radionucleotide coupled) anti CD20 mAb (in 
lymphoma) 
6) Immunostimulatory mAbs, that facilitate immune response by balancing 
immunosuppressive mechanisms, e.g. ipilimumab targeting CTLA-4 (in melanoma). 
3.3 Active immunotherapy 
General considerations 
Active specific immunotherapy principally involves the use of TCV, with the aim to evoke 
a tumor specific immune response in cancer patients. 
The major challenge in developing a successful TCV strategy is shifting the balance 
from tolerance to self-antigens towards a long-lasting therapeutic anti-tumor immunity, 
without inducing autoimmune toxicity to normal cells.  
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Animal models have played a crucial role in understanding the mechanisms of tumor 
immunology and different modalities of immunization and experimental models have been 
employed to determine whether TAAs can induce immune responses that are able to 
hamper the growth of a clinically manifest cancer.  
The promising results have driven the attempts to move these applications from bench 
to bedside. To this day, however, only three vaccines have been approved by the Food and 
drug administration (FDA) for use in humans; Cervarix® and Gardasil® (in fact 
constituting preventative measures towards development of cervical carcinoma) and 
sipuleucel-T (Provenge®), a cellular preparation for therapy of metastatic hormone-
refractory prostate cancer. In the veterinary field an immunotherapeutic DNA vaccine 
encoding human tyrokinase, Oncept™, has been approved as TCV for malignant 
melanoma a in dogs. Oncept™ generates an effective antibody response against the dog 
tyrokinase and prolongs the lives of dogs even with advanced stage disease. 
3.3.1 Tumor associated antigen for therapeutic cancer vaccines 
Virtually any mutant, overexpressed or abnormally expressed protein in cancer cells, can 
serve as a target for cancer vaccines. Since the pivotal work done by pioneers in 
oncoimmunology, characterization and identification of hundreds of TAAs has been 
conducted and additional insights into the mechanisms whereby TAAs can break self-
tolerance and elicit an immune response has been provided. Simply put, TAAs can be 
classified into four classes, see Table 1. 
 
Table 1. Tumor antigens 
Classes of tumor antigens [69] 
(1) Truly exogenous, non-self TAAs (invariably of viral origin) 
(2) Unique, mutated TAAs (stemming from cancer cell-specific genetic alterations) 
(3) Idiotypic TAAs (the unique way whereby the B cell receptor expressed by some clonal 
hematopoietic malignancies is rearranged) 
(4) Shared TAAs (which are also expressed by normal cells, mostly at lower levels) 
 
Shared TAAs include cancer-testis and differentiation antigens that are either silent or 
expressed at only low levels in normal tissue but are transcriptionally activated in certain 
tumors e.g. CEA in CRC and human telomerase reverse transcriptase (hTERT) in 
pancreatic cancer. 
Optimally designed TCV should combine the best tumor antigens and delivery 
strategies to achieve a clinical result. A National Cancer Institute (NCI) immunotherapy 
workshop was held in 2007 to rank agents with high potential to serve as 
immunotherapeutic drugs. The ranking was based on the likelihood for efficacy. A priority-
ranked list of cancer antigens weighed the criteria for the “ideal” cancer antigen to provide 
focus for prioritized translational research [70]. The resulting criteria were as follows: (1) 
therapeutic function, (2) immunogenicity, (3) role of the antigen in oncogenicity, (4) 
specificity, (5) expression level and percentage of antigen-positive cells, (6) stem cell 
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expression, (7) number of patients with antigen-positive cancers, (8) number of antigenic 
epitopes and (9) cellular location of antigen expression. 
3.3.2 Desired mechanisms of action of TCV 
The processes required to mount an effective anti-tumour response can be subdivided into 
four different steps [71]. In the first, TAAs must be captured, processed and presented by 
DCs (or directly presented by tumour cells). The second step requires suitable 
activation/maturation signals that allow DC to differentiate migrate to lymph nodes and 
present TAAs to naïve T cells. The third step involves expansion of T cells in sufficient 
numbers capable of recognizing and eliminating tumour cells. In the final step, antigen-
educated T cells must leave the lymph node, traffic to infiltrate the tumour and persist long 
enough to kill the malignant cells. 
Thus CD4+, CD8+ T cells, and B cells can all be activated in the immune response 
against cancer. For intracellular TAAs, CD8+ CTLs may be the primary effector cell, but 
the activity and longevity of these will likely be enhanced by CD4+ Th1 cell activation. For 
cell surface antigens, both CTL and humoral responses may mediate antitumor activity, 
again attesting to the importance of activating both CD8+ and CD4+ T cells [72].  
 
Figure 2. Summary of 
potential effector 
mechanisms involved in 
antitumor immunity induced 
by vaccine. Immature or 
intermediate dendritic cells 
acquire the antigen(s) at the 
site of vaccination. In 
response to maturation and 
activation signals, dendritic 
cells migrate to draining 
lymph nodes, upregulate 
costimulatory molecules, 
such as B7, and present 
tumor-associated antigen-
derived peptides (13-25-mer) 
to cognate CD4+ T-cells in 
the context of MHC class II 
molecules. The interactions 
of additional costimulatory 
signals, such CD40-CD40L, 
further promote dendritic cell 
maturation providing help for 
efficient priming and 
activation of CD8+ T-cells. 
[3]. Dendritic cells can present 
8-11-mer peptides derived 
from endogenous antigens (e.g., viral vector-encoded tumor-associated antigens) or exogenous antigens 
(e.g., recombinant protein vaccine) in the context of MHC class I molecule to CD8+ T-cells. CD4+ T-
cells producing Th1 cytokines, such as IL-2, further contribute to the clonal expansion of CD8+ T-cells 
[73, 74]. Tumor-specific CD8+ T-cells migrate to the sites of tumor metastasis where they encounter 
peptide-MHC complexes presenting the tumor antigen on tumor cells. CTLs are able to kill tumor cells 
by perforin-mediated cell lysis or apoptosis mediated through granzymes. CTLs can also kill target cells 
through death receptor mediated apoptosis via Fas ligand or TNF-related apoptosis inducing ligand 
(TRAIL). CTLs secreting IFN-γ and TNF-α (or TNF-β) may elicit direct or indirect cytotoxic activity[73].  
[5]. Activated CD4+ T-cells may also kill tumor cells by using similar pathways as CTLs. CD4+ T-cells 
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producing Th1 cytokines may stimulate effector cells of the innate immune system, such as macrophages, 
NK and natural killer T-cells, which might exert antitumor effects by several mechanisms. CD4+ T-cells 
secreting Th2 cytokines may attract and activate eosinophils releasing their cytocidal granule content. 
Th2 cells may also activate B-cells producing antibodies, which may activate B-cells producing 
antibodies, which may contribute to tumor cell destruction by ADCC and CDC [74, 75]. Antibodies may 
also induce an idiotypic network cascade or tumor-cell apoptosis. 
ADCC: Antibody-dependent cellular cytotoxicity; CDC: Complement-dependent cytotoxicity; CTL: 
Cytotoxic T-lymphocyte; IFN: Interferon; IL: Interleukin; MHC: Major histocompatibility complex; NK: 
Natural killer; NO: Nitric oxide; TCR: T-cell receptor; Th: T-helper; TNF: Tumor necrosis factor. 
(Reprinted with permission from Expert Review of Vaccines. Mosolits et al. [76] Copyright 2014). 
3.4 Adjuvants 
Adjuvants are substances or interventions that, combined with an antigen, enhance its 
immunogenicity and the desired type of immune response. The preferred type of response 
in cancer is one in which IFN-γ producing Th1 lymphocytes and cytotoxic T lymphocytes 
predominate. Adjuvants discussed here fall into one of the following categories: biological 
or chemical adjuvants and cytokines/chemokines. 
 
 Biological adjuvants are recognized as non-self and known to induce migration of 
APCs at the site of delivery and hence the induction of an inflammatory response. 
APCs may then capture and process TAA at the same site. The most commonly used 
biological adjuvant is the bacillus Calmette-Guerin (BCG), diphtheria toxin and 
tetanus toxoid.  
 Chemical adjuvants function similarly to biological ones and some, for example, 
aluminium hydroxide (alum) and incomplete Freud´s adjuvant (IFA) provide a matrix 
that sequesters antigen at the delivery site, allowing a timed release of antigen to 
APCs. 
 Cytokines used for decades include GM-CSF and IL-12, known for inducing 
recruitment, migration, stimulating cross-presentation of DCs and promoting Th-1 
differentiation. GM-CSF is known to augment both humoral and cellular immunity, 
although immune suppression may be seen at high doses [77, 78]. GM-CSF also induces 
the expansion of NKT cells that may contribute to immunity against tumors [79]. 
 Microbes often elicit immune responses by activating pattern-recognition receptors 
such as members of the Toll-like receptor (TLR) family. TLR-signalling play an 
important role in both the innate and acquired immune system and TLR agonist has 
been evaluated as adjuvants. TLR agonists, such as unmethylated CpG-motifs (CpG) 
and lipopolysaccarid (LPS) derivate monophosphoryl lipid A (MPL) have been in the 
focus for evaluation lately. However, the use of TLR agonists is often associated with 
severe toxicity, resulting from non-specific activation of lymphocytes [80]. 
3.5 Therapeutic cancer vaccines approaches 
A plethora of active vaccination strategies exist with attributed advantages and 
disadvantages. 
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Discussed in this thesis: 
 Whole cell-based vaccines 
 Dendritic cell vaccine strategies 
 Peptide and protein vaccines 
 DNA vaccines 
 
Whole cell-based vaccines  
Whole cell-based vaccines have been investigated for decades. They have the advantage to 
deliver a diverse panel of TAA and to simultaneously provide both CD8+ and CD4+ 
epitopes, and particularly autologous tumor-cell derivate potentially include unique TAAs. 
Autologous or allogeneic tumor cells are processed (lysates or irradiated cells) to optimize 
the release of their antigens, and are injected together with adjuvants or haptens. However, 
it is difficult to obtain and individually prepare vaccines for each patient. To avoid this 
problem, tumor cell vaccines have been prepared from allogeneic tumor cell lines. This is 
feasible as many tumors have overlapping antigen expression [81, 82]. This is attractive as 
tumor antigen-specific immune responses can be initiated by cross-priming, by-passing the 
need to match the MHC haplotype of the patient to the vaccine platform [83].  
 
Dendritic cell vaccine strategies  
Dendritic cell vaccine strategies are attractive as activated and mature DCs express high 
levels of both MHC Class I and II molecules for priming of CD8+ and CD4+ T cells, and 
additionally have co-stimulatory signals for T cell activation. By providing DCs with TAA 
it is possible to induce tumor-specific immune responses. Vaccination strategies based on 
DCs can be divided in to three categories.  
The 1st group encompasses strategies where DCs are generated by culturing patient-
derived hematopoietic progenitor cells or monocytes with specific cytokine combinations 
in the presence of adjuvants and loaded with TAAs ex vivo. The DCs are then re-infused to 
the patient, most often i.d., together with an adjuvant. Ex vivo DC vaccines exhibit a good 
safety profile and can induce TAA-specific CD8+ and C4+ T cells, as seen with the 
approval of CD-based vaccine Sipuleucel-T for use in patients with prostate cancer [84].  
The 2nd group of promising DC vaccine strategies comprise TAA delivery to DC in 
vivo and is achieved by coupling TAAs to monoclonal antibodies or other vectors that 
recognize specific DC surface receptors [85]. Encouraging results for in vivo – targeted 
vaccination came from the use of engineered lentiviral vectors encoding the human 
melanoma antigen NY-ESO-1[86, 87] .  
The 3rd group includes approaches based on DC-derived exosomes [85]. DC derived 
exosomes (small membrane-surrounded vesicles originating from fusion of plasma-
membrane and multivesicular bodies, released by DCs) are 100-fold more enriched with 
MHC Class II molecules than DCs. They have shown to be capable of inducing immune 
responses once loaded with TAAs and inoculated in vivo in animal models [85]. 
 
Protein and peptide vaccine 
Protein and peptide vaccine (Papers I and IV) strategies are based on the administration of 
high doses of the TAA(s) in order to load empty MCH molecules on APCs. 
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Tumor–derived peptide epitopes constitute the simplest cancer vaccine formulation 
delivered i.d. together with an adjuvant [88], but this strategy requires prior knowledge to the 
precise definition of MHC Class I and II epitopes and are thus HLA-restricted. Other 
drawbacks include the weak immunogenicity of short peptides. Many immunodominant 
epitopes from TAAs have a low to intermediate binding affinity for the MHC molecule and 
are subdominant epitopes recognized by low affinity T cells that have escaped central 
tolerance. The tumor may also have ceased to express the epitope (antigen-variant escape 
mutants). The immunogenicity may be enhanced by introducing lipid, carbohydrate or 
phosphate groups, by introducing protease-resistant peptide bounds and thereby prolonging 
the peptides half-life in vivo [89]. On the other hand, manufacturing on a large scale is 
affordable and peptide vaccinations are safe with no potential for recombination. The 
greatest advantage of immunizing with MHC Class II peptides is the concomitant 
generation of CD4+ cells T cells, particularly the generation the Th1 subtype, essential for 
the generation of a robust CTL response. It is anticipated that the peptide is intracellulary 
processed to yield shorter CD8+ epitopes [12]. These are presented by APCs on MHC Class 
I molecules (cross-presentation) to produce a CTL response, ensuring a maximal immune 
response. 
 
DNA vaccines 
Unlike other vaccines, DNA vaccines (Papers II and III) do not contain the antigens 
themselves but are simple vehicles for in vivo transfection and antigen production. The 
circular DNA plasmid is made of the plasmid backbone, containing the origin of 
replication, the antibiotic resistance gene, a transcriptional unit that contains the eukaryotic 
promoter, the transgene(s), and a polyA tail that aids in the stability and translation of the 
messenger ribonucleic acid (mRNA) [90]. A schematic picture is shown in Figure 3. 
 
Figure 3. Basic design of plasmid DNA 
vaccine vector. Therapeutic and prophylactic 
DNA vaccines for Human 
immunodeficiency virus (HIV-1). 
(Reprinted with permission from Copyright 
Clearance Center (Expert Opinion of Biological 
Therapy. Ramirez et al [90]. Copyright 2014) 
 
 
These plasmids are delivered in the form of circular DNA or within appropriate delivery 
vectors to the intradermally, subcutaneously or intramuscularly by various delivery 
methods. 
In all scenarios, using the host cellular machinery, the plasmid enters the nucleus of 
transfected local cells, including resident APC [91]. Here, gene expression from the plasmid 
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is followed by generation of the transgenes(s) [91]. DNA vaccines induce protein synthesis 
in vivo increasing the possibility to utilize both the MHC Class I and II antigen presenting 
pathways to induce humoral as well as CD4+ and CD8+ T cell responses [91, 92]. The 
relevant epitopes do not need to be defined, nor is the vaccine limited to particular HLA 
genotypes, as the whole protein will be produced and processed in the host cell. 
However, whereas professional APCs are very efficient at direct presentation, 
myocytes and keratinocytes are not, as they express detectable yet rather low levels of 
MHC Class I and co-stimulatory molecules [92, 93]. The induction of immunity following 
TAA expression must then proceed via cross-presentation (see Section 1.6). 
 
As compared to cell-based and recombinant preparations many advantages with DNA 
plasmids exist. They are stable at room temperature, can thus be stored without effort and 
are rapidly produced in bacteria in high amounts at low cost [94]. Additionally, DNA 
vaccines are inherently immunogenic due to CpG motifs in the DNA backbone, able to 
bind and activate specific TLR who constitute part of the innate immune system [89, 90] and 
as mentioned previously DNA plasmids need not be HLA specific to elicit an immune 
response as the whole protein will be produced in the host cell.  
DNA vaccines are also highly flexible and can be designed to encode both TAA and 
immunological components that may enhance the immune response. They can be 
engineered to express non-self-proteins (in additions to the TAA gene) that exert adjuvant 
effects, as fragments of tetanus toxin [95], pseudomonas aeruginosa exotoxin [96] or other 
immunostimulatory factors, such as cytokines, including IL-2, IL-12 and GM-CSF [69]. 
Furthermore, the plasmids can be engineered to alter the intracellular routing of the TAAs, 
resulting in the preferential activating of humoral (when TAAs are targeted to the 
endoplasmatic reticulum where folding and secretion can occur by adding a gene coding 
for a signal sequence) or cellular (if TAAs are targeted to the cytosol or – by adding genes 
encoding for ubiquitin aimed to enhance degradation and peptide production in the 
proteosome) immunity [97, 98]. 
A major safety concern has been mutagenesis, which may trigger oncogenes. Studies 
using DNA vaccines has however not exhibited mutagenesis [99]. No association between 
plasmid DNA and genomic DNA were seen in mice following DNA vaccination, towards 
HIV-1 [100]. Vaccine-related adverse events in humans were mild and tolerable using the 
same DNA vaccine [101].  
For plasmid immunization, the aim is to rapidly induce an immune response, while for 
safety reasons; the plasmid should preferably be cleared rapidly from the body. During the 
efforts to prove the safety of plasmid DNA, the biodistribution of plasmids have been 
studied in several animal species, and the results all indicate that the plasmid is rapidly 
cleared from the body [100] and found exclusively at the site of injection at later time points. 
Additionally, studies with DNA vaccines have shown that even after multiple 
immunizations, anti-DNA antibodies are not produced [91]. 
The vast majority of clinical trials with DNA vaccines to date have utilised naked 
DNA plasmids. 
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3.6 Delivery route and delivery systems 
Induction of tolerance or activation of immune cells may depend on the nature of the TAA, 
but also the formulation, dose, route, delivery system and schedule of the vaccine. In 
particular, delivery of DNA vaccines has been the focus for attention for a long time. 
Intramuscular injections were commonly used during early tests with large animals and 
humans resulting in relatively poor efficacy although robust immune responses were seen 
in mice [69]. This probably stems from the fact that the efficacy of DNA vaccines 
administered i.m. strictly depends on the injected volume. A high hydrostatic pressure not 
only augments the uptake of the DNA vaccine by myocytes and resident APCs but also 
promotes tissue damage, resulting in the release of danger signals [69]. Scaling up the 
volume needed for DNA vaccines i.m. to humans is not always feasible why alternative 
routes have been sought for. Some DNA vaccine delivery methods have focused on 
delivering DNA to skin due to the presence of large quantity of immune cells there, 
including APCs and lymphocytes, in comparison to muscle [90]. 
 
Electroporation (EP) (Paper III) has been used, to enable molecules to be delivered 
intracellularly ex vivo, for several years and has recently been tested in vivo to aid in 
transfecting cells. EP consists in the electrical stimulation of skin or muscle immediately 
after delivery of naked DNA. EP delivers a local controlled electrical field to cells, 
unstabling the cellmembranes and thereby allowing molecules, such as plasmids, to easily 
penetrate the cells and enhancing transfection [102, 103] While the electrical field is applied 
transient pores appear after which the cell can either heal-closing off the pores, or die due 
to lysis depending on the length and amount of the electrical field exposure [90]. I.m. EP is 
associated with an increase in transfection efficacy (enabling less injected volume) and 
local tissue injury resulting in danger signals [69]. 
EP i.m has been the most commonly used technique in preclinical models for practical 
reasons [104] but could prove difficult in translational human studies due to painful muscle 
contractions. In mice skin electroporation was performed after prostate-specific antigen 
(PSA) DNA administration i.d. A robust PSA-specific CD8+ T cell response was induced 
after one single DNA injection [104]. Laddy et al conducted a head-to-head comparison of 
EP-augmented i.m. and i.d delivery of equal amounts of influenza virus-encoding plasmids 
in monkeys. Results revealed that i.m. EP induced the highest levels of cellular immune 
responses, whereas i.d. EP was superior for induction of antibodies [105]. 
The introduction of in vivo electroporation for increasing the uptake and 
immunogenicity of plasmid vaccines raised concerns that the method might affect the 
persistence of plasmid DNA in the target tissue and pose a risk of integration into the host 
genome. In mice, immunized and EP-augmented with a HIV DNA plasmid, no association 
between plasmid DNA and genomic DNA could be detected [100]. 
Details about a needle-free jet-injection device, Biojector (Paper II, III), will also be 
discussed within the scope of this thesis. Biojector, is a CO2-propelled device that injects 
plasmids as a highly focused liquid stream and is distributed in the i.d. or i.m depending on 
the amount of pressure used [106]. This has been shown to enhance antigen expression as 
compared to conventional needle, most probably due to a larger area and thus larger 
number cells being targeted [107]. In a mice model, a plasmid CEA66-DNA vaccine 
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construct, was safe and induced both CEA-specific CD4+ and CD8+ T cell responses (IFN-
γ) when delivered i.d. by Biojector, however humoral responses were weak [108]. 
Gen-gun immunization is carried out by propelling DNA-coated gold particles into 
the cells of the skin and Langerhans cells, which were shown to migrate rapidly to regional 
lymph nodes [109], generating CD8+ T cell responses. 
The potency of the gen-gun approach was shown in a clinical trial in humans; patients 
had not generated immunity to the licensed recombinant HBsAg vaccine but did produce 
antibodies following gene gun-delivered hepatitis B surface antigen (HBsAg) DNA[110]. 
Newly developed i.d. tattoo DNA vaccine delivery consist of fine metal needles that 
oscillate at a high frequency and puncture the skin, leading to transfection of skin 
associated cells. Robust T cell responses have been seen in a phase I melanoma studies [111]. 
3.7 Immunomodulating strategies 
For TCV to be successful, both sides of the adaptive system must be manipulated. The 
effector system should be stimulated and the suppressor system inhibited. 
Combination therapies may produce synergistic antitumor responses and certain 
chemotherapeutic agents, rather than being immunosuppressive can, under certain 
conditions act as strong adjuvants for active immunotherapy [112, 113]. Drugs may induce 
immunogenic tumor cell death resulting in emission of danger signals and TAA [114]. 
Secondly, chemotherapy may indirectly stimulate immune components, by inducing 
transient lymphodepletion, by affecting immunosuppressive mechanisms or by stimulating 
immune effectors [115].  
Cyclophosphamide, a nitrogen mustard alkylating agent, is used for treatment of a 
variety of tumors. However, the biological activities of cyclophosphamide are dose-
dependent [115]. Although regarded as immunosuppressive, cyclophosphamide has been 
shown to act as a strong immunomodulator for active immunotherapy when used with 
carefully defined doses [112, 113, 116]. Historically, 300 mg/m2 has been used for enhancing 
immunotherapies in phase III trials [117]. Treatment with low-dose cyclophosphamide has 
been shown to transiently reduce Treg levels and enhance tumor-reactive T cell responses 
when used alone or in combination with active immunotherapy [118, 119]. 
Novel monoclonal antibodies can directly antagonize immune suppressive check 
points, (CTLA-4 and PD1), they target lymphocyte receptors or their ligands in order to 
enhance the antitumor activity [57].  
Two fully humanized antibodies; ipilimumab and tremelimumab, exist. Ipilimumab is 
approved for treatment of advanced melanoma since 2010. In combination with TCV, a 
randomized three-arm trial of patients with advanced melanoma showed survival benfit for 
ipilimumab ± vaccine. Patients received either: a peptide vaccine of melanoma-specific 
pg100 alone; the gp100 vaccine plus ipilimumab; or ipilimumab alone. There was a 3.5 
month survival benefit for patients in both groups receiving ipilimumab compared to the 
group receiving gp100 alone [120]. 
Clinical experience with PD1 antibodies is less extensive than CTLA-4, but initial 
results look promising [121]. 
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4 IMMUNOTHERAPY TARGETING CEA AND 
hTERT 
4.1 Carcinoembryonic antigen 
CEA, a member of the immunoglobulin family of molecules, is a cell-surface-expressed 
180 kDa glycoprotein. Many functions have been linked to CEA. CEAs primary role is in 
cellular adhesion and it dimerizes through a unique two-point intracellular adhesion 
mechanism and can interact with several intergrins in the intercellular matrix, suggesting 
that it may promote malignant cell proliferation and metastasis. It has been shown to inhibit 
cell death induced by loss of anchorage to the extra cellular matrix. Also, it promotes cells 
entering G0-like state, thus facilitating accumulation of additional oncogenic events [122-124]. 
CEA has been shown to induce cellular secretion of cytokines that promote cellular 
adhesion, thereby increasing the malignant potential of cells overexpressing this protein 
[125]. 
In the adult human body, CEA protein expression is low. CEA is normally expressed 
to a low level in gastrointestinal epithelium and to a higher extent during fetal development. 
CEA expression in colorectal tissues indicated a CEA tissue content below 300 ng/mg 
protein in healthy donors, less than 2000 ng/mg protein in normal mucosa of cancer 
patients, and 200 to >10 000 ng/mg of protein in tumor biopsies [125]. It is overexpressed in 
nearly all colorectal cancers and to a high extent overexpressed in pancreatic 
adenocarcinomas, breast cancer and non-small-cell lung cancers [126]. In cancer patients, 
significantly augmented cell-surface expression of CEA has been associated with more 
advanced disease and increased relapse rates compared to patients expressing lower levels 
of CEA. Neoplastic tissues can secrete CEA into the bloodstream, where it can be used as a 
serological circulating marker, mainly in colorectal cancer [125]. 
The CEA molecule is synthesized as a precursor protein with N- and C-terminal signal 
peptides. These signal peptides target the protein through the endoplasmatic reticulum 
(ER), where it is heavily glycosylated, and subsequently to the cell membrane [125]. More 
than 50% of the molecule consists of N-linked oligosaccharides on 28 potential sites of N-
glycosylation [127]. Both signal peptides are removed during post-translational processing. 
The mature protein consist of a 107-amino acid N-terminal Ig V-like region; three 178 
amino acid C2 Ig-like repeating units called A1 B1, A2 B2 and A3 B3, respectively; and 
finally, the C-terminal signal peptide has been replaced by a glycophosphatidylinositol 
(GPI) membrane anchor [126] [72]. Furthermore, CEA may have different molecular weights 
in normal vs. cancer cells due to different N-glycosylation pattern in cancer cells [128] where 
hypoglycosylation is associated with tumorigenesis. 
CEA protein is processed and presented on major histocompability complex (MHC) 
proteins for multiple alleles, including HLA A2, A3 and A24. T –lymphocytes from 
healthy volunteers and cancer patients can recognise processed epitopes of CEA and can 
become activated to lyse CEA-expressing tumors.  
 
CEA has as a TAA been identified as an attractive target for vaccination approaches against 
multiple types of cancer due to its pattern of expression and its likely function in 
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tumorigenesis. In a well-vetted priority-ranked list, composed to prioritize TAA for 
translational research based on predefined criteria, CEA ranked no.13 of 75 [70]. 
4.2 Therapeutic cancer vaccines targeting CEA 
Several studies have shown that CEA can be used as a target for cancer immunotherapy 
protocols. It has previously been demonstrated that tolerance to CEA could be interrupted 
by mouse immunization with recombinant human CEA without leading to autoimmune 
disease [129-131]. Among the diverse CEA-based cancer vaccines in humans, DCs pulsed 
with agonist epitopes of CEA and recombinant virus-based vaccines have been most 
successful [128]. 
4.2.1 Dendritic based vaccines 
Matsuda et al performed a pilot study on eight patients with advanced gastrointestinal 
malignancy [132]. HLAA24-positive patients received CEA peptide-pulsed DCs 
subcutaneously (s.c.) every two or three weeks. One patient had a dramatic decrease of 
CEA-levels. The other patients experienced disease progression, except three who had 
disease stabilization lasting for 3, 4 and 5 months respectively. In a phase I-II study, the 
effect of DCs transfected with RNA encoding CEA was evaluated [133]. Twenty-nine 
patients with advanced cancer expressing CEA were included. Two patients had minor 
response, 3 patients showed stable disease (SD) lasting more than two years and 18 
underwent progression.  
4.2.2 Recombinant virus-based vaccines 
PANVAC is a cancer vaccine delivered through the viral vectors rV and vF, both of which 
include transgenes for epithelial mucin 1 (MUC1) and CEA in combination with specific 
costimulatory molecules (TRICOM). Early clinical trials have demonstrated PANVACs 
safety and ability to activate antigen-specific T cell responses [134]. PANVAC in 
combination with GM-CSF was evaluated for efficacy in 25 patients with metastazised 
CRC, lung, breast gastric or ovarian carcinomas. Multiple previous chemotherapy 
treatments and short time since last chemotherapy treatment correlated with lack of 
immune response. Three patients had prolonged SD or improvement and partial response 
(PR) was seen. Several patients had prolonged survival [135]. A second clinical trial 
evaluated PANVAC in combination with GM-CSF in 26 patients with metastatic breast or 
ovarian cancer [136]. SD was seen in four patients, with progression free survival (PFS) of 4-
6 months and overall survival (OS) 16.1-40.5 months. Minor response and on case of 
complete response (CR) was seen. A significant reduction in circulating Tregs and increased 
CD4+ T cell responses were observed in the patient with CR an in another patient with SD.  
In a set of Phase I trials, patients with stage III/IV pancreatic cancer who received 
PANVAC showed a slight increase in survival [134]. This led to a Phase III trial in which 
PANVAC was compared to best supportive care or second-line chemotherapy in patients 
who had failed first-line chemotherapy with gemcitabine [134]. The trial did not meet its 
primary endpoint of improved OS, possibly due to poor trial design that is – administering 
vaccine as a monotherapy to an inappropriate patient population [134]. An ongoing Phase II 
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trial is evaluating PANVAC in patients with CRC after complete resection of liver or lung 
metastasis. 
4.2.3 Recombinant protein vaccines 
Patients vaccinated with a recombinant CEA protein in combination with GM-CSF 
mounted a humoral and cellular immune response of a significantly higher magnitude than 
patients in the non-GM-CSF group. A positive correlation between the anti-CEA IgG titer 
and overall survival was suggested [137, 138]. 
4.2.4 Yeast vaccines 
Non-pathogenic yeast-strain has been shown to be effective vectors for TCV and can 
stimulate antigen-specific cellular and humoral immune responses without inducing 
neutralizing antibodies [139, 140]. They can be administered multiple times to increase 
immune response with no toxicity and are easy to produce [141]. Twenty-five patients with 
metastatic CEA-expressing carcinomas were treated with recombinant yeast designed to 
express CEA. Five patients had SD > 3 months and five patients showed evidence of CEA-
specific T cells [142]. 
4.3 hTERT 
Telomeres are specialized structures at the end of human chromosomes composed of 1000-
2000 non-coding repeats of TTAGGG nucleotide DNA sequences. They serve as protective 
“caps” at the end of chromosomes protecting them from DNA degradation and unwanted 
repair [143-145]. In normal human cells telomeres shorten with each successive cell division, 
and upon reaching critical lengths they elicit DNA-damage responses, thus activating cell 
cycle check points, leading to cell apoptosis. In contrast, cancer cells which develop 
chromosomal aberrations show activation or re-activation of telomerase upon exposure to 
DNA damage signal, thereby bypassing cell cycle checkpoints and leading to uncontrolled 
growth and proliferation [145, 146]. 
Telomerase is a human ribonucleoprotein reverse transcriptase (hTERT) composed of 
two main subunits: the catalytic protein hTERT and the ribonucleopotein template hTER 
[143, 144, 147]. Telomerase synthezises telomeric DNA by continually adding single stranded 3´ 
end of telomere in the 5´ to 3´ direction [143, 145, 148]. Telomerase, and specifically its catalytic 
subunit hTERT, is overactive in 85-90% of most cancers [147] and has become a widely 
accepted target for anticancer therapeutics. In normal non-malignant cells telomerase is 
present in embryonic, male germline and some adult stem cells. In most somatic cells 
telomerase is present in very low or almost non-detectable levels and is less active 
compared to cancer cells [149]. 
One of the advantages of targeting telomerase is that rapidly progressive cancer cells 
have shorter telomeres compared to normal somatic cells and stem cells, that have not yet 
reaches critical lengths, due to end replication problem that occurs as a result of aging[150, 
151]. By de novo synthesising TTAGGG repeats, telomerase can maintain cancer cell 
telomeres at stable length at all times, ensuring their immortal capacity. The difference in 
telomere length and activity in normal cells and cancer cells explains therapeutic 
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cytotoxicity on cancer cells while having minimal impact on normal cells [152]. Chronic 
lymphocytic leukemia (CLL) patients have been shown to exhibit spontaneous T cells 
recognizing GV1001, (a hTERT-peptide, see Section 4.4.1) which could lyse autologous 
telomerase expressing leukemic cells [153] cells. In a well-vetted priority-ranked list, 
composed to prioritize TAA for translational research based on predefined criteria, hTERT 
ranked no.23 of 75 [70]. 
4.4 Therapeutic cancer vaccines targeting hTERT 
There are two general strategies of telomerase targeting in cancer treatment. One is 
targeting directly by inhibiting the activity of its catalytic subunit (hTERT) or its RNA 
template (hTER), leading to inhibition of telomerase activity, telomere shortening and 
inhibition of cell proliferation. Another strategy is to target the telomerase subunit 
indirectly via G-quadruplex stabilizers, tankyrase or HSP90 inhibitors, thus blocking 
telomerase access to telomeres or inhibiting binding of telomerase-associated proteins 
leading to telomere uncapping and cell apoptosis [154, 155]. The latter do not constitute 
immunotherapeutic modalities. Targeting of hTERT from an immunological standpoint 
will be discussed in this section. 
Since telomerase is present in most cancers, its peptides are considered shared TAAs. 
They are however capable of producing strong immune response by eliciting both CD4+ 
and CD8+ T cell responses, potentially leading to tumor cell lysis [155-157]. 
4.4.1 GV1001- hTERT peptide-based vaccine 
GV1001 is a 16 amino acid HLA Class II restricted hTERT-peptide, which consists of 
amino acids 611-626 of the hTERT active site [158-160] and is capable of binding to 
molecules encoded by multiple alleles of all three loci of HLA Class II [161]. These 
characteristics of the hTERT peptide might virtually enable all patients, irrespective of 
HLA-type, to present one or more immunogenic epitopes to effector cells. GV1001 is 
administered as an MHC Class II peptide, which is endogenously processed to yield a 
MHC Class I peptide producing both CD4+ and CD8+ responses. The activity of CD4+ T 
cells leads to a secretion of IFN-γ and IL-2, further stimulating CD8+ CTL´s and NK cells, 
which may help to increase the infiltration and the retention of CD8+ T cells into the tumor 
sites leading to an up regulation and re-expression of MHC Class I molecules. This may 
have a therapeutic advantage in patients with advanced cancers where loss of MHC Class I 
is seen [162, 163]. 
Several strategies are employed in the development of vaccines that may induce 
hTERTs immunogenicity and eliminate the issue of self-tolerance, such as the use of 
adjuvans like GM-CSF or TLR-7 agonist (imiquimod), used in GV1001 vaccine strategies 
[160, 162]. This may prevent the rapid degradation and elimination of anticancer vaccine 
peptides before recognition by APCs, which may occur due to self-tolerance to self-
peptides [160, 164].  
GV1001 has completed several phase I and II studies conducted in patients with 
advanced stage melanoma, hepatic cellular carcinoma and in patients with pancreatic 
cancer [149]. Forty-eight patients with unresectable pancreatic adenocarcinoma were given 
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i.d. injections of GV1001 at three dose-levels along with GM-CSF for 10 weeks followed 
by monthly boosters. Delayed-type hypersensitivity (DTH) and in vitro T cell proliferation 
was measured. Of the 27 evaluable patients, median survival for the intermediate group 
(300 nmole GV1001) was 8.6 months, which was significantly longer than the low and 
high-dose groups. One-year survival in the intermediate group was 25% [165].  
Two other phase III studies with GV1001 in patients with nonresectable pancreas 
cancer were Primo Vax and Telo Vac. The Primo Vax trail examined vaccine monotherapy 
versus gemcitabine but was terminated due to lack of survival advantage. The Telo Vac had 
three arms; sequential gemcitabine/capecitabine; and concurrent gemcitabine/capecitabine 
and vaccine. The results are pending. Another study is evaluating radiation therapy, 
tadalafil, sargramostim, gemcitabine and GV1001 in patients with unresectable pancreatic 
cancer and is ongoing, Clinical Trials.gov identifier NCT01342224. 
4.5 Immune monitoring 
Technologies available for measuring immune responses are numerous. It is critical to 
select an assay that can accurately measure therapy-induced changes in the frequency 
and/or function of immune cells. Briefly, phenotypic markers, functional assessments or 
cellular product may be assayed [166]. Phenotypic assays include measurement of absolute 
cell numbers and cell frequencies by flow-cytometry and tetramer binding. Functional 
assays include DTH, proliferation, cytotoxicity assays (ADCC, CDC) and enzyme-linked 
immunosorbent spot (ELISPOT). Assays for cellular products include enzyme linked 
immunosorbent assay (ELISA) (immunoglobulin levels, cytokines) and 
chemokine/cytokine levels (Multiplex).  
 
In patients treated with TCV, three single-cell assays for detection of antigen-specific 
effector T lymphocytes can be used for monitoring: ELISPOT, cytokine flow-cytometry 
(CFC) and tetramer binding.  
Each of these is based on T cell receptor recognition of cognate peptides presented by 
MHC Class i/II molecules on the surface of APCs to the responder T cells. They have in 
many ways replaced “bulk assays” as cytotoxicity assays and proliferation assays. 
However, no consensus exits as to which of these three should be selected to best monitor 
vaccination results [166]. ELISPOT measures function of individual responder cells by 
identifying those that produce and secrete the measured cytokine, CFC measures cytokine 
expression in a cell and not its actual secretion [166]. Tetramer binding detects peptide-
specific T cells expressing the relevant TCR but may also bind non-functional T cells [167]. 
However, CFC and tetramer binding are flow-cytometry based and can provide information 
about identification of responding cells.  
 
Simultaneous assessment of multiple biomarkers, for example multiplex assay may provide 
the investigator with an “immune profile”. Multiplex assays have all but replaced ELISA 
detection for cytokines allowing simultaneous measurement of, for example, suppressive 
cytokines, proinflammatory cytokines and Th1 vs Th2 cytokines [166]. For further details see 
Table 6. Polychromatic flowcytometry enables further examination of cells. mAbs labelled 
with various chromatophores with various excitation wavelengths is used to identify and 
determine levels of expression of surface or intracytoplasmic markers.  
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Table 6. Assays used for immune monitoring in vaccine clinical trials 
Assay  Brief description  Advantages  Disadvantages
1 DTH  Ag as soluble protein is injected i.d. and the 
diameter of erythema or induration is 
measured after 48‐72 h 
• only in vivomeasure available
• easy to perform 
•  no standardized cut‐off for a positive 
response 
•  no standardized dose for DTH 
 testing 
•  Ag‐specificity is questionable 
•  Mainly mediated by CD4+ effector 
memory T cells 
2 ELISPOT  Lymphocytes are cultured with the Ag 
studied in a micro‐titer plate coated with a 
monoclonal Ab to a specific soluble factor 
(e.g. IFN‐, IL‐4, IL‐10, TNF‐). The cells and 
the Ag are then washed from the wells and 
replaced with secondary antibody 
conjugated to a detection reagent. The 
plate is developed with a chromogen and 
spots appear where there was a cell 
secreting the soluble factor being 
investigated. 
• functional assay
•  allows  to  measure  individual  soluble 
factors  secreted  by  activated  T  cells  and 
identify  the  pathway  of  the  immune 
system activated by the vaccine 
•  Lowest  limit  of  detection  (1/100000  Ag‐
specific T cells) 
• considerably reliable 
• relatively rapid  
•  provides no information on cell 
phenotype 
•  Responder‐stimulator interactions may 
result in unacceptable high background 
spots  
 
3 Tetramer staining  Tetramers are composed of four MHC‐I 
molecules, each bound to the epitope of 
interest. The tag is a fluorescent label, 
which allows to measure the binding of the 
tetramer to the TCR at flow‐cytometry. 
 
• sensitive (1/100000 Ag‐specific T cells)
• T cell subset analysis is optimal 
• allows to identify the peptide sequence or 
epitopes that bind to the highest number 
of TCR in a naïve individual 
• allows to  identify the phenotype of the T 
cell to which the tetramer binds 
•  allows  to  measure  the  change  in  the 
number  of  T  cells  displaying  a  particular 
TCR before and after vaccination 
•  requires knowledge of the epitope
•  requires availability of the tetramer for 
the respective epitope/HLA allele  
•  unable to distinguish between 
functional and dysfunctional T cells 
4 Cytokine Flow  
Cytometry 
(CFC) 
Lymphocytes are cultured with the Ag 
studied and the presence of intra‐cellular 
cytokines is detected by fluorescein‐labelled 
mAb. The phenotype of the lymphoid cells 
(CD4+, CD8+, etc) is identified with a second 
set of fluorescein‐labelled mAbs. 
• functional assay 
• sensitive (1/10000 Ag‐specific T cells) 
•  provides  additional  information  on  cell 
phenotypes 
• relatively rapid 
•  non‐specific background staining
5 Lympho‐
proliferation assay 
Lymphocytes are cultured with the Ag 
studied. 3H thymidine is added to the 
culture medium. Proliferating (dividing) cells 
incorporate 3H thymidine, which is 
quantitated using a beta scintillation 
counter 
• easy to perform
• reliable 
• sensitive 
• reproducible 
•  can be influenced by the non‐specific 
immune function of the patient 
•  can be influenced by the in vitro 
stimulation procedure 
•  not qualitative 
•  not quantitative 
•  no information about responding cell 
population (CD4+, CD8+, etc) 
6 Cytotoxicity assay 
 
Lymphocytes previously sensitized to the Ag 
present on the target cells are cocultured 
with the target cells. Percentage of lysis of 
target cells is quantitated by 51Cr release 
assayor by Flow Cytometry 
• functional assay
• measures the ability of direct tumor lysis 
•  low sensitivity 
•  often involves multiple in vitro 
stimulations 
•  not quantitative 
•  often other targets than autologous 
tumor are used, which may not reflect 
the capability of effector cells to lyse 
autologous tumor cells in vivo 
7 Multiplexing for 
cytokines 
A mixture of an infrared dye with a red dye 
is incorporated into polystyrene beads. The 
concentration ratio of both dyes is varied to 
produce beads which emitt a well‐defined 
fluorescence spectrum upon excitation. 
Each bead is indentified by its unique 
colour, and can be coupled with a capture 
molecule specific for a ligand of interest, 
e.g. like a protein. The mixture of the beads 
is quantitatively analyzed in a FACS‐like 
fluorescence‐activated bead sorter 
• Used as cytokine profiling Th1/Th2
• Small sample volume fluid 
• High throughput 
•  Sera measurement may be  less useful 
than in situ measurement 
Adapted from  [Palma et al. 2007 [168]] 
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4.6 Clinical endpoints  
The gold-standard for confirmatory trials is OS but evaluation of OS in clinical trials is a 
lengthy process, suggesting the need to identify surrogate endpoints for markers of 
efficacy. A number of surrogate end-points for OS exist including time to progression 
(TTP), PFS and disease-free survival (DFS), but such endpoints may not accurately predict 
the outcome of OS. This was exemplified in the study concerning Sipuleucel-T, previously 
mentioned above. The primary end-point of TTP was not met, but there was a trend 
towards improved OS in the treatment group [169].  
Furthermore, in order to show clinical efficacy, measurements of tumor progression is 
often made by using the Response Evaluation Criteria in Solid Tumors (RECIST), which 
defines the response to treatment according to size [170]. However, this may not always 
reflect the efficacy of immunotherapy. Anecdotal data suggest that increase in tumor size 
may be due to increased inflammatory infiltrates. For example, the administration of mAb 
targeting the immunosuppressive receptor CTLA4 has been shown to double the survival 
of Stage IV melanoma patients in the absence of early tumor shrinkage [120]. 
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5 COLORECTAL CANCER 
5.1 Epidemiology 
CRC is the third most common cancer in both men and women, and the fourth leading 
cause of cancer deaths in the world [171]. The estimated worldwide incidence of CRC is 1.2 
million per year [171]. In Sweden approximately 6000 patients are diagnosed with a 
colorectal cancer every year, see Table 3 [172]. 
 
Table 3. Colorectal cancer incidence (total number) in Sweden 2011 
Tumour site Female Male Total 
Colon 2102 2081 4183 
Rectum 821 1158 1979 
Total 2923 3239 6162 
 
Mean age at diagnosis was 72 years for colon cancer and 70 years for rectal cancer in 
patients diagnosed during 2000-2007 [173]. A screening program for early detection 
commenced in 2008 in the Stockholm-Gotland region, and plans are to further expand this 
nationwide in late 2013. The vast majority of CRCs, about 95% constitute of 
adenocarcinomas. 
5.2 Clinical staging 
To select the optimal therapeutic strategy for a patient with CRC, a correct clinical and 
pathological staging is of great importance. Furthermore, the clinical and pathological 
staging at diagnosis is a crucial prognostic factor [174]. 
Preoperative standard staging involves endoscopy of the rectum and colon, computer 
tomography (CT) of the chest and abdomen, and in rectal cancer, an additional magnetic 
resonance imaging (MRI) of the pelvis. 
The diagnosis of an adenocarcinoma in the colon or rectum is made by biopsy of the 
tumor. In order to select the optimal treatment strategy for CRC patients, the results of the 
staging procedure are discussed at a multidisciplinary team (MPT) conference [175]. 
5.2.1 Tumor-Node-Metastasis staging 
Collected data is condensed according to a staging system, based on the depth of extension 
of the carcinoma through the bowel wall (T), the presence or absence of lymph node 
metastases (N) and the presence or absence of distant metastasis (M). Historically, Duke´s 
classification system has been used, but the TNM staging system by American Joint 
Committee on Cancer (AJCC) and International Union Against Cancer (UICC) is now 
recommended. Details on TNM staying system and comparison to Duke classification 
system are shown in Table 4. In the revision of the TNM system to the 7th edition, further 
subclassifications were added [176]. In our studies we have used the Dukes classification 
system in Paper I and AJCC TNM 5th Edition in Papers II and III. In our studies we used 
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Duke’s classification system in Paper I and AJCC TNM 5th Edition in Papers II-III, see 
Table 4. 
 
Table 4. 
 TNM Stage 7th Edition  TNM Stage 5th and6th Edition Duke’s 
Stage T N M Stage T N M  
0 Tis N0 M0 0 Tis N0 M0 – 
I T1-2 N0 M0 I T1-2 N0 M0 A 
IIA T3 N0 M0 IIA T3 N0 M0 B 
IIB T4a N0 M0 IIB T4 N0 M0 B 
IIC T4b N0 M0     B 
IIIA T1-2 
T1 
N1/N1c 
N2a 
M0 
M0 
IIIA T1-2 N1 M0 C 
C 
IIIB T3-T4a 
T2-T3 
T1-T2 
N1/N1c 
N2a 
N2b 
M0 
M0 
M0 
IIIB T3-4 N1 M0 C 
C 
C 
IIIC T4a 
T3-T4a 
T4b 
N2a 
N2b 
N1-N2 
M0 
M0 
M0 
IIIC Any T N2 M0 C 
C 
C 
IVA Any T Any N M1a IV Any T Any N M1 D 
IVB Any T Any N M1b     D 
 
Tumor-Node-Metastasis Classification 
 AJCC 7th Edition AJCC 5th and 6th Edition 
 T (primary tumor) 
TX Primary tumor cannot be assessed Primary tumor cannot be assessed 
T0 No evidence of primary tumor No evidence of primary tumor 
Tis Carcinoma in situ: intra epithelial or 
Invasion of lamina propria 
Carcinoma in situ: intra epithelial or 
Invasion of lamina propria 
T1 Tumor invades submucosa Tumor invades submucosa 
T2 Tumor invades muscularis propria Tumor invades muscularis propria 
T3 Tumor invades through the muscularis propria into 
pericolorectal tissues 
Tumor invades through the muscularis propria into 
pericolorectal tissues 
T4 Tumor directly invades other organs or structures 
and/or perforates visceral peritoneum 
Tumor directly invades other organs or structures 
and/or perforates visceral peritoneum 
T4a Tumor penetrates to the surface of the visceral 
peritoneum 
 
T4b Tumor directly invades or is adherent to other 
organs or structures 
 
 N (Regional lymphnodes) 
NX Regional lymph nodes cannot be assessed Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastases No regional lymph node metastases 
N1 Metastases in 1 to 3 regional lymph nodes Metastases in 1 to 3 regional lymph nodes 
N1a Metastases in one regional lymph node  
N1b Metastases in 2 to 3 regional lymph node  
N1c Tumor deposit(s) in the subserosea, mesentery, or 
non peritonealized pericolic or perirectal tissues 
without regional nodal metastases 
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N2 Metastases in 4 or more regional lymph nodes Metastases in 4 or more regional lymph nodes 
N2a Metastases in 4-6 regional lymph nodes  
N2b Metastases in 7 or more regional lymph nodes  
 M (Distant metastases) 
MX Distant metastases cannot be assessed Distant metastases cannot be assessed 
M0 No distant metastases No distant metastases 
M1 Distant metastases Distant metastases 
M1a Metastases combined to one organ or site (for 
example lung, liver, ovary, non-regional node) 
 
M1b Metastases in more than one organ/site or the 
peritoneum 
 
 
The TNM system defines the stage, see Table 4, and the 5-year survival for patients with 
CRC is directly related to the clinical and pathological staging at the time of diagnosis. It 
varies between 95-100% for stage I, 75-90% for stage II, 45-60% for stage III and about 
10% for stage IV, reported in a recently published Swedish follow-up study [177, 178].  
5.3 Treatment 
5.3.1 Surgery 
Surgery is the primary treatment in CRC and the goal is to remove the tumor together with 
its regional lymphatic drainage and blood supply. The total mesorectal excision (TME) 
approach for rectal cancer, described in 1982, has reduced the rates of local recurrence 
considerably [179]. 
Patients in the palliative patients are offered surgery of the primary tumor if 
complications such as bleeding, perforation or obstruction may or do occur. 
5.3.2 Non-surgical treatment of CRC 
Adjuvant treatment/Colon cancer 
The aim of adjuvant treatment is to prevent local recurrence, distant metastases and to 
prolong survival. Postoperative chemotherapy has been advocated for colon cancer in 
Sweden since the mid nineties. Currently, 6 months of adjuvant chemotherapy is 
recommended, although ongoing studies are investigating shorter periods of treatment as 
well as administering part of the chemotherapy preoperatively. Treatment might commence 
within 8 weeks after surgery [180-182]. 
Controversy still exists regarding the role of standard adjuvant chemotherapy for stage 
II colon cancer disease [183]. Factors associated with a higher risk of recurrence include T4 
stage, perforation at presentation and inadequate node sampling (less than 12 nodes). 
Tumor grade and lymphovascular invasion are more controversial in this regard. All these 
factors are associated with a higher risk of recurrence but they are not predictive of a 
benefit from adjuvant chemotherapy, (i.e they are not prognostic markers). The TNM 
staging system has its limitations. For example, stage II patients who display mismatch 
repair deficiency (microsatellite instability, which is not included in the TNM system), 
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have an excellent prognosis following radical surgery and do not appear to benefit from 
adjuvant 5-fluorouracil (5-FU) [184]. Regarding the use of oxaliplatin in stage II patients, 
there is no evidence for the addition of this to 5-FU [185]. Stage II patients need to be 
considered carefully for chemotherapy based on all available clinical individual data. 
In stage III colon cancer, combination of oxaliplatin and 5-FU is recommended for 
most patients. However, the benefits of oxaliplatin are less clear when the risk of 
recurrence is low (e.g. low grade, T1/2 or N1 disease) or the treatment related risks are 
high, such as those with comorbidity, elderly or poor performance status [185-187] and 
capecetabine monotherapy is a reasonable alternative in these situations [188]. Irinotecan, 
widely used in metastatic colorectal cancer (mCRC), has failed to improve survival in the 
adjuvant setting [189, 190].  
Likewise, biological agents have been disappointing and are not routinely used in the 
adjuvant setting. The addition of the antiangiogenic monoclonal antibody targeting VEGF, 
Bev has not improved 3-year disease free survival (DFS) [191].  
Adding the anti-EGFR-targeted monoclonal antibody Cet to adjuvant chemotherapy 
has also proven disappointing in both Kirsten rat sarcoma viral oncogene (KRAS) wild-
type and KRAS mutant tumors [192], thus the identification of a predictive/prognostic 
biomarker has not yet affected adjuvant therapy selection as it has for mCRC. 
5.3.3 Curative treatment of rectal cancer 
Neoadjuvant therapy in rectal cancer often involves radiation therapy. The introduction of 
more precise surgery, TME and the use of pre or postoperative radiation therapy or 
radiochemotherapy have contributed both to much lower local recurrence rates and 
improved survival and more accurate preoperative staging with MRI and a series of trials 
have established radiotherapy as standard care [193, 194]. Radiation therapy, alone or with 
chemotherapy is given not only to the 10-15% non-resectable but also to much less 
advanced tumors, and in Sweden the standard is to give RT before surgery.  
Two different preoperative approaches are mainly used. The short-course consists of 
25 Gy in 5 Gy fractions given during 5 days, followed by surgery the following week. The 
long-course consist of 45-50.4 Gy given in 1.8-2.0 Gy fractions concomitant with 5-FU, 
either given as bolus or as capecitabine [193, 195, 196].  
Patients are grouped according to their MRI-staging results and considered for 
radiation therapy. Tumors labelled as “good” receive no radiation therapy before surgery, 
tumors labelled as “bad” receive short-course radiation therapy and tumors labelled as 
“ugly” receive long-course radiation therapy, see Table 5 [197].  
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Table 5.  
 Good Bad Ugly 
Low tumor T1-2, N0,mrf- T3,N1-2,mrf- T4,T3 mrf+ 
Lateral lymphnodes+ High tumor T1-T3b,N0,mrf- T3c-d,N1-2,mrf- 
Cut-off between low/high tumors is at app. 8 cm from the anal verge 
mrf; Mesorectal fascia 
mrf+ Tumors growing adjacent to the mesorectal fascia 
mrf- Tumors not growing adjacent to the mesorectal fascia 
Extramural vessel invasion (not mentioned above) is labelled as at least “bad” 
Adapted from Blomqvist, Glimelius. Acta Oncologica, 2008; 47:5-8. 
 
Opinions on adjuvant chemotherapy vary a great deal in the literature. Some authors 
advocate that chemotherapy ought to be given applying the same criteria as in colon cancer, 
whereas some advocate that although surgery and preoperative (chemo)radiotherapy was 
adequately performed – the value of adjuvant chemotherapy has not been established [198]. 
Swedish National Guidelines suggest the following recommendations: 
 Adjuvant chemotherapy is recommended to patients with highrisk-criteria rectal 
cancer stage II and stage III patients to whom preoperative radiation therapy was not 
given.  
 Adjuvant chemotherapy may be considered in patients with highrisk-criteria stage II 
and stage III patients who received short-course radiation therapy and surgery the 
following week. 
 Adjuvant chemotherapy may be considered in patients with highrisk-criteria stage II 
and stage III patients operated 4-6 weeks after preoperative short-course radiation 
therapy. 
 
The uncertainty is even greater regarding patients who receive long-course radiation 
therapy and 5-FU preoperatively. The addition of oxaliplatin in the adjuvant setting has not 
been evaluated. A small retrospective study compared adjuvant 5-FU-based chemotherapy 
with no treatment in patients with T3-4 rectal cancers [199]. The results showed no 
significant impact on adjuvant chemotherapy on PFS or OS, although a difference seemed 
to emerge at approximately, respectively, 2 and 5 years after start of preoperative treatment. 
Patients in whom no down staging was seen did not benefit from adjuvant chemotherapy, 
indicating that the same prognostic factors may drive both tumor sensitivity for the primary 
treatment and long-term benefit from further adjuvant chemotherapy.  
An alternative approach is to administer the CT preoperative, as is currently evaluated 
in the Rapido trial, Clinicaltrial.gov identifier NCT01558921. Primarily “ugly” tumors are 
included. To guarantee control of the rectal tumor short course radiation therapy is given 
followed by systemic chemotherapy (capecitabine and oxaliplatin) before surgery. The 
investigators hypothesize that with this protocol both the local tumour and possible micro 
metastases are effectively treated and that this will result in an increased survival. The 
investigators will compare this with the standard treatment of long-course radiation therapy 
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followed by TME surgery and adjuvant chemotherapy (capecitabine and oxaliplatin). I.e all 
patients in the standard arm receive adjuvant chemotherapy. 
5.3.4 Metastatic CRC 
In selecting the optimal treatment for mCRC, the initial consideration is whether the aim is 
curative (initially or potentially resectable disease) or noncurative.  
At the time of diagnosis approximately 15% of the patients with stage IV CRC have 
metastatic disease in the liver and less than 10% have pulmonary metastases that are 
resectable [200, 201]. The majority of patients with mCRC and liver metastases are considered 
unresectable at presentation, although a minority of these patients may eventually be able to 
be treated with curative intent if a good response to chemotherapy is achieved. Complete 
resection of limited liver metastases and/or lung metastases is the only potentially curative 
treatment for mCRC with a survival rate after hepatectomy of 40-60% if patients are 
carefully selected [202, 203].  
Affecting the choice of treatment are factors relating to the patient (age, performance 
status, comorbidities, patients preferences) and those relating to the tumor (potential 
resectability, disease burden, symptoms, rate of progression, prognostic biomarkers and 
prior treatment history).  
Doublet chemotherapy is recommended if an aggressive approach is indicated, i.e to 
stabilize rapidly progressive disease, in order to reduce metastasis where surgery is possible 
and in first-line resectable patients. 5-FU is the backbone in doublet chemotherapy. There 
are little differences in efficacy between doublets of 5-FU-infusion/capecitabine and 
oxaliplatin (FOLFOX and XELOX) or 5-FU-infusion/capecitabine and irinotecan 
(FOLFIRI and CAPIRI) regimens [174]. Single chemotherapy (5-FU) is recommended in 
non-rapidly progressive nonresectable disease. 
Patient outcome is further improved by the addition of a biological agent to these 
chemotherapy regimens, why this may be added to the treatment of potentially resectable 
mCRC patients and non-resectable patients. 
The addition of Bev to both irinotecan and oxaliplatin based doublet chemotherapy 
significantly improves PFS and with irinotecan, OS in mCRC patients, but with smaller 
effects on resection rates [204, 205].  
The benefit of EGFR-antibody (Cet or panitumumab (Pan)) treatment to KRAS 
wildtype (WT) tumors are highly variable in trials. Unlike antiangiogenics, a predictive 
marker exists for EGFR-targeted therapy. KRAS gene mutation (MT) is predictive of 
nonresponse to EGFR-targeted therapy either as a single agent or in combination with 
irinitecan and oxaliplatin based chemotherapy and in standard care EGFR-antibodies are 
only recommended to KRAS WT patients. KRAS mutations in codon 12 are most 
common, but mutations in codon 13 constitute approximately 15% of all KRAS mutations 
[174]. Conflicting data exists on whether KRAS MT in codon 13 are eligible for treatment 
with EGFR-targeted therapy [174]. Furthermore, CRC tumors, defined as KRAS WT may 
harbour other oncogenic alterations (BRAF, NRAS) in which the benefit of EGFR-targeted 
therapy is yet unknown [174]. However, large Phase III studies have shown OS benefit 
provided by Cet and PFS benefit for both Cet and Pan in KRAS WT patients. EGFR-
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targeted therapy with Cet or Pan also generally improves RR in KRAS WT patients by over 
10% when added to doublet chemotherapy [206, 207].  
The use of triplet chemotherapy, 5-FU/irinotecan and oxaliplatin, (FOLFOXIRI) for 
first line mCRC has been investigated in Phase III studies with an unclear survival benefit 
compared with double chemotherapy. FOLFOXIRI significantly increased resection rate, 
complete resection rate after surgery, PFS and OS compared [208] to FOLFIRI in one study, 
while in another study, FOLFOXIRI was not superior to FOLFIRI [209]. Toxicity is a major 
concern and FOLFOXIRI is therefore not part of standard treatment, but may be considered 
in selected patients. 
5.3.5 Second-line treatment and beyond 
For most patients, progression following an oxaliplatin doublet will result in a switch to 
irinotecan-based therapy and vice versa. PFS is shorter than with first-line therapy [210]. If 
single chemotherapy was given, registry data suggest oxaliplatin based doublet 
chemotherapy [211]. KRAS WT patients, not previously exposed to Cet or Pan, may receive 
this as third-line therapy alone or in combination with irinotecan. The choice of biological 
agent in second line therapy is an area of active research with ongoing Phase III studies. 
Aflibercept in second-line treatment combined with FOLFIRI and regorafenib in late-stage 
disease has shown survival gains in recently reported trials and may become part of 
standard treatment [174]. Summary of proposed management for mCRC is seen in Figure 4. 
 
 
Figure 4. Proposed chemotherapy management algorithm for metastatic colorectal cancer. †If aim is 
downstaging or bulky and symptomatic disease is present in KRAS WT patients, anti-EGFR should also 
be considered.EGFR: EGF receptor; MT: Mutation; PD: Progressive disease; WT: Wild-type.  
(Reprinted with permission from Copyright Clearance Center. Expert Reviews of Anticancer Therapy. 
Price et al [174]. Copyright 2014) 
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6 PANCREATIC CANCER 
6.1 Epidemiology and prognosis 
Pancreatic cancer is currently one of the deadliest of the solid malignancies. The annual 
incidence in Sweden is approximately 11 cases per 100 000 inhabitants. In Sweden, 1580 
people died due to pancreatic cancer in 2011 [172]. Approximately 85% of the patients have 
advanced spread disease at the time of diagnosis and only 15-20% of the patients are 
eligible for curative surgery. Following curative surgery, 90 % of the patients will relapse. 
Despite decades of effort, the 5-year survival rate remains at only 5% and the median 
survival reported for resected pancreatic cancer patients ranges from 17-27 months [212]. 
In the sections that follow, “pancreatic cancer” (PC) will refer to invasive ductal 
adenocarcinoma of the pancreas. 
6.2 Risk factors 
Both environmental and inherited factors contribute to the development of PC. The most 
common risk-factor is smoking. Studies has shown that current smokers have a 2.2 fold 
increased risk of PC than never smokers and approximately 25% of PC are attributable to 
smoking [213, 214]. Long standing type 2 diabetes of >10 years duration have a 1, 5 
foldincrease compared with nondiabetics [215]. Increased body mass index (BMI) is an 
independent risk factor [216]. Heavy alcohol consumption and chronic pancreatitis also 
elevates the risk of PC, the latter 2.7-fold. Individuals with a family history of PC have a 
1.9-13-fold increased risk, based on case-control and cohort studies [212]. Inherited 
(germline) mutations in the BRCA2 gene, PALB2 and Lynch syndrome are all associated 
with higher risks [212].  
6.3 Staging 
A contrast-enhanced thin-slice CT scan of the thorax, adomen and pelvis is performed in 
the staging procedure. Optimal treatment depends on careful staging and all patients should 
be discussed in a multidisciplinary team. In the absence of metastatic disease, the 
relationship of the tumor to the adjacent major vessels defines resectability. Resectable 
stages include stage I and II, and the subset of stage III that is defined as borderline 
resectable. Less than 180-degree involvement of the celiac axis or superior mesenteric 
artery is considered stage III borderline resectable. Greater than 180-degree involvement, is 
considered locally advanced or unresectable PC [217, 218]. AJCC/UICC and TNM definitions 
for pancreatic exocrine cancer are shown in Table 6. 
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Table 6. AJCC/UICC stage groupings and TNM  
definitions for pancreatic exocrine cancer 
AJCC/UICC 
stage 
TNM 
0 Tis,N0,M0 
1A T1,N0,M0 
IB T2,N0,M0 
IIA T3,N0,M0 
IIB T1,N1,M0 
T2,N1,M0 
T3,N1,M0 
III T4,any N,M0 
IV Any T, Any N, M1 
TNM Classification for Exocrine pancreatic cancer. Adapted from AJCC Cancer Staging manual.7th ed, 
NY: Springer, 2010, pp 241-9  
Primary tumor (T) 
TX Primary tumor cannot be assessed 
T0 No evidence of primary tumor 
Tis Carcinoma in situ  
T1 Tumor limited to the pancreas, less than 2 cm in greatest dimension 
T2 Tumor limited to the pancreas, more than 2 cm in greatest dimension 
T3 Tumor extends beyond pancreas but without involvement of the celiac axis or the 
superior mesenteric artery 
T4 Tumor involves the celiac axis or the superior mesenteric artery  
Regional lymph nodes (N) 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Regional lymph node metastasis 
Distant metastasis (M) 
M0 No distant metastasis 
M1 Distant metastasis 
6.4 Treatment 
6.4.1 Surgery 
Patients with Stage I/II disease are recommended immediate surgical resection followed by 
adjuvant chemotherapy. The low chance of long-time survival after surgery, mentioned 
above, and considerable morbidity in 40-60% of the patients following major surgery needs 
to be considered when selecting patients [212]. Complete recovery can take 2-3 months even 
in the absence of complications.  
6.4.2 Neoadjuvant therapy 
The advantage with neoadjuvant chemotherapy is 1; down-staging of some locally 
advanced tumors, (conversion rates vary between 15-40%) [219], 2; it spares the 15-35% of 
patients who develop metastatic disease during treatment the risks of a major operation [212] 
and 3; guarantees that almost all patients receive some form of chemotherapy or radiation 
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therapy as postoperative complications may prevent postoperative treatment. In resectable 
patients neoadjuvant chemotherapy delays the curative surgery and systemic chemotherapy 
is therefore given postoperatively. 
Stage III borderline patients should be recommended neoadjuvant therapy prior to 
surgery. Patients with stage III locally advanced disease should be treated with 
chemotherapy or chemoradiotherapy – a few of these patients may be considered for 
surgery.  
Similar neoadjuvant regimens are often used for locally advanced and unresectable 
disease, i.e. Stage III with greater vessel involvement. The combination of 5-FU, LV, 
irinotecan and oxaliplatin (FOLFIRINOX) , the combination of gemcitabine, docetaxel and 
capecitabine and gemcitabine alone are used, typically followed 5-FU infusion, 
capecitabine or gemcitabinebased chemoradiation to 45-54 Gy in 1,8 to 2,5 Gy fractions or 
36 Gy in 2,4 Gy fractions [212]. Surgery is performed within 6-8 weeks following 
completion of neoadjuvant therapy. Neoadjuvant chemotherapy to patients with Stage I/II 
is controversial [212]. 
6.4.3 Adjuvant therapy 
Six months of adjuvant chemotherapy with either 5-FU or gemcitabine is recommended 
[212]. When gemcitabine was compared with observation in PC patients, DFS and OS were 
6,9 months and 20,5 months for the observation arm, and 13,4 months and 24,2 months for 
the treatment arm [220]. A randomized trial between adjuvant elongated bolus 5-FU or 
gemcitabine showed similar OS of 23 months, with higher but acceptable rates of diarrhea 
in the 5-FU group and haematological toxicity in the gemcitabine group [221]. 
Chemoradiation adjuvant to the tumor bed is being explored, but has not reached standard 
practice. 
Other adjuvant regimens are being evaluated. The combination of interferon-alfa, 
cisplatin and 5-FU with adjuvant chemoradiation had a median OS of 32 months compared 
to 28,5 months in the treatment arm with 5-FU alone [212]. Erlotinib has been studied and 
was safe to combine with gemcitabine as well as with concomitant capecitabine and 
chemoradiation adjuvant [212]. 
In a phase II setting immunotherapy was combined with a pancreatic cancer vaccine of 
irradiated GM-CSF transfected allogenic whole-cell tumor lines. The median OS was 24, 8 
months and patients who demonstrated a CD8+ T cell response to mesothelin had a higher 
likelihood of remaining disease-free [222].  
6.4.4 Metastatic disease 
Since 1997, gembitabine has been the standard treatment in the metastatic patient and 
hence tested with various other agents in doublet chemotherapy regimens [223]. Capecitabine 
coupled with gemcitabine has not shown superiority over gemcitabine alone, but may be 
considered in frail patients not eligible for single gemcitabine [224]. Nor has gemcitabine 
plus oxaliplatin or cisplatin shown significantly improved OS in phase III trials [212]. 
Adding docetaxel and capecitabine to gemcitabine has albeight in small studies, 
demonstrated good disease control rates and may be considered for patients with good 
performance status [225].  
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Gemcitabine has also been tested with targeted therapy, the combination of 
gemcitabine and erlotinib improved OS minimally [226]. The addition of Cet to gemcitabine, 
or of Bev both demonstrated no survival benefit and added toxicity [227, 228].  
FOLFIRINOX has emerged as a new promising regimen for fit patients in comparison 
to gemcitabine. Disease control rate and median OS were 70% and 11.1 months in the 
FOLFIRINOX arm, compared to 51% and 6, 8 months in the gemcitabine arm with intact 
quality of life [229].  
As for second line, patients treated with gemcitabine should be considered for a 5-FU 
based treatment, either alone or coupled with oxaliplatin or irinotecan [212].  
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7 AIMS 
The overall aim of this thesis was to investigate immunogenicity of rCEA-protein, CEA-
DNA and hTERT-peptide vaccination. 
 
 To analyse the induction of IgM, IgA and IgE anti-CEA response in CRC patients 
without macroscopic disease, immunized with rCEA ± GM-CSF. 
 To determine the safety of CEA66-DNA vaccination delivered by needle-free injection 
in combination with GM-CSF in CRC patients. 
 To investigate the cellular and humoral immune response following CEA66-DNA 
vaccination delivered by Biojector or tetwtCEA-DNA-vaccination followed by 
electroporation as adjuvant treatment in CRC patients. 
 To analyse the cellular and humoral immune response after priming with CEA66-DNA 
vaccination and boosting with tetwtCEA-DNA vaccination in CRC patients. 
 To explore the immunogenicity and safety of GV1001 vaccination combined with GM-
CSF and gemcitabine as first-line treatment in patients with advanced pancreatic 
adenocarcinoma. 
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8 MATERIAL AND METHODS 
8.1 Patients  
All patients included in this thesis were recruited and treated at the Department of 
Gastrointestinal Cancer at the Karolinska University Hospital, Sweden.  
8.1.1 Healthy donors 
Healthy donors were recruited from the staff at the laboratory at Cancer Centre Karolinska 
(CCK). In Paper I, four healthy donors were analysed in the flow cytometry, the CDC and 
the ADCC analysis. No healthy donors were included in Paper II. 
In Paper III and IV, nine healthy donors respectively were analysed in the proliferation 
assay, ELISPOT assay and flow-cytometry. 
8.2 Methods 
8.2.1 Immune assays 
Blood sampling was performed in the clinic and handled in a standardized fashion. All 
assays were carried out at the adjacent CCK laboratory – except for ELISA in Paper I and 
III. In Paper I, ELISA was performed at the Department of Clinical Chemistry at 
Ängelholm Hospital and in Paper III ELISA was performed at the Swedish Institute for 
Infectious Control. Used immune assays are displayed in Table 7. 
 
Table 7 
Assays 
used 
Prolif. ELISPOT 
(INF-γ) 
Cytokine 
secretion  
DTH ELISA Flowcytometry CDC ADCC 
Paper I     X X* X* X* 
Paper III X X X  X  X**   
Paper IV X X X X   X**   
*In one patient only. **T cell subsets, NK cells, NKT cells and MDSC. 
8.2.2 Proliferation assay 
Peripheral blood mononuclear cell (PBMC), 1x105/well, were cultured with the rCEA 
protein (Paper I), or GV1001, the ras-peptide and the HIV-peptide (Paper IV), purified 
protein derivative of tuberculin (PPD) (Papers III, IV), phytohemagglutinin (PHA) (Papers 
III, IV) and tetanus toxoid (TT) (Paper III) in 96-well culture plates for 6 days. During the 
last 18 hours of incubation, 1 Ci/well 3H thymidine was added. Cells were harvested and 
incorporated radioactivity was measured by a beta-counter. Results are shown as a 
stimulation index (SI) calculated by dividing mean radioactivity (cpm) of 6 replicates of 
experimental wells by that of the background value (cells with medium alone). Cells 
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stimulated with PPD, PHA, TT served as positive controls. Cells stimulated with HIV 
served as a negative control.  
A change in ratio ≥ 2 on at least two occasions, compared to baseline, was considered 
significant [230].  
8.2.3 ELISPOT (IFN-γ) 
PBMCs were cultured in 48-well plates with rCEA (Paper III), a pool of CEA peptides 
(Paper III), PHA and PPD and TT (Papers III, IV) for 5 days. A millipore 96-well filter 
plate was coated with anti-IFN-γ antibody. Cultured PBMC were transferred to the coated 
plate and incubated for 20 h with the antigens as above. Cells were washed and incubated 
with a secondary biotinylated anti-IFN-γ antibody for 2 hours at room temperature. After 
washing, Streptavidin-ALP conjugate was added to the cells and incubated for 1 hour at 
room temperature. Cells secreting IFN-γ were developed by adding substrate BCIP/NBT 
plus and incubated at room temperature for 5 min. The reaction was stopped at the 
appearance of dark spots. Spots were counted by an automatic ELISPOT assay reader.  
Paper III: A vaccine induced IFN-γ response in ELISPOT was defined as an increase 
in delta value (experimental value minus background) at least two-fold compared to 
baseline [231]. 
Paper IV: A vaccine induced IFN- response was defined if all of the following criteria 
were fulfilled: i) Spotforming units (SFU) of stimulated wells significantly higher (p<0.05) 
than of unstimulated wells (background) and at least twice that of the background, ii) SFU 
of cells stimulated with the control peptide not significantly (p>0.05) higher than 
background; iii) SFU of a post-vaccination test at least twice that of the pre-vaccination test 
[230]. The non-parametric Mann Whitney two-tailed rank sum test was used for comparison 
of unstimulated vs stimulated cells in Paper IV. 
8.2.4 Cytokine secretion assay 
Supernatants were collected (20 l/well) after 24 and 120 hours of incubation from the 
proliferation assay and stored at -70°C until analyzed. The volume was replaced with 
complete medium. IL-4, IL-10, IFN-, TNF- and GM-CSF were analyzed (Paper III, IV). 
Standard concentration curves were generated. The coefficient of variation (mean ± SD of 
the individual analytes) of PHA stimulated cells was calculated.  
Cytokines concentration (pg/ml) in supernatants of antigen stimulated cells divided by 
that of cells alone using the highest value at 24 or 120 hours culture periods respectively 
was used. Post vaccination ratios divided by prevaccination ratios at different time points 
are shown. A ratio ≥ 1, 5 (Paper III) and ≥ 2 (Paper IV) (relative increase) was considered 
an antigen induced specific response [232]. 
8.2.5 DTH 
GV1001 (0.112mg) in 0.1ml saline (groups A/B) was injected intradermally in the volar 
part of the forearm. GV1001 (0.105mg) in 0.22 ml saline (group C) was injected 
intradermally in the lower abdominal wall. The skin test was read, by the patient, after 48 
hours by measuring the diameter of induration (mm). A positive DTH response was 
defined as ≥ 5 x 5 mm of induration (Paper IV). 
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8.2.6 ELISA 
The levels of IgM, IgA and IgE antibodies against rCEA were assayed by conventional 
isotype-specific sandwich ELISA (Paper I) [233]. Wells were coated with recombinant 
human CEA (2 ug/ml) and serum samples were assayed at 1:500 (IgM), 1:200 (IgA) and 
1:10 (IgE) dilutions. Following overnight incubation in the wells antibodies were detected 
with alkaline phosphatase (ALP)-conjugated rabbit polyclonal isotype-specific F(ab’)2-
fragments (IgM and IgA) and biotinylated anti-IgE mAb/ALP-conjugated streptavidin (19) 
after 2h/2h incubations, respectively.  
The antibody levels were calculated from standard curves established with chimeric 
IgM, IgA2 and IgE anti-NIP (5-iodo-4-hydroxy-3-nitro-phenacetyl acid) hapten antibodies 
[233, 234] using BSA-NIP conjugate (10 ug/ml) as coating antigen. This procedure permits 
comparison of results between runs in a semi-quantitative way where 1 AU (arbitrary 
ELISA unit) approximates to 1 ng of antibody as previously described [233]. The sensitivities 
of the IgA, IgM and IgE antibody assays in serum are 0.1 ug/ml, 2 ug/ml and 0.4 ng/ml, 
respectively. 
In Paper III, conventional isotype-specific sandwich ELISA was also performed. Plates 
were coated with 0.1 μg per well of rCEA or purified hCEA diluted in 0.05 M Na2CO3 (pH 
9, 6) and incubated at room temperature overnight followed by 24 h in 4°C. After washing 
in ELISA buffer (0.05% Tween20, 0.15 M NaCl in distilled water), the plates were blocked 
by 5% milk in PBS for 2 h. Sera from immunized patients were diluted in 2.5% milk in 
PBS, and added to the plates (1:4 – 1:10000). Following incubation over night at room 
temperature, excess serum was removed and the plates were washed with ELISA buffer. To 
detect CEA-specific IgG antibodies, a rabbit anti-human HRP conjugate (1:3000 in 1.25% 
milk) was added to the plates and incubated at 37°C for 2 h. Plates were washed with 
ELISA buffer and developed by adding O-phenylene diamine substrate activated with 
H2O2. The reaction was stopped by adding 2.5 M H2SO4. Optical density (OD) was read at 
490 and 650 nm. A net absorbance of 0.5 was used as a cutoff. A monkey anti-CEA serum 
served as a positive control.  
A patient was considered to have developed a significant response if IgM, IgA or IgE 
(Paper I) and IgG (Paper III) antibodies could be detected at at least two different time 
points and was at least twice that of the pre-immunization value for that patient. 
8.2.7 Flowcytometry 
Indirect immunofluorescence using flow cytometry  
In paper I, SW48 (a human cancer cell line expressing CEA) and A549 (a human lung 
cancer cell line not expressing CEA) were used for surface staining of a patient serum, 
pooled sera from healthy donors (HD) and a non-relevant IgA isotype control (22). Briefly, 
10
6 
cells were washed in PBS containing 0.01% sodium azide and incubated with the IgA 
isotype control, HD and the patient serum (1:10–1:1000) at 4°C for 1 h followed by 3 
washings. A polyclonal rabbit anti human IgA serum (1:100) in washing buffer was then 
added and incubated at 4°C for 1 h. The cells were finally washed 3 times and fixed by 
adding 1% paraformaldehyde in PBS. Cells were analyzed by flow cytometry. 
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Cellular staining and flow cytometry 
Briefly conjugated antibodies were added to cells (5x105 cells per tube) and incubated for 
30 min. Intracellular staining was performed using a T-reg staining kit. After a nal wash, 
cells were resuspended in PBS and events acquired using LSRll and analyzed by the 
FlowJo software (Paper III, IV).  
8.2.8 Complement dependent cytotoxicity (CDC) 
Stored sera (-70°C) from a patient who had developed high IgA anti-CEA antibody titers 
were used (Paper I). Two sampling times were pooled to obtain a sufficient amount of 
serum. IgA from the patient and pooled sera from healthy donors were isolated using 
peptide M/Agarose affinity column chromatography yielding highly purified IgA. 
Briefly, as previously described [235], SW48 (a human cancer cell line expressing CEA) 
and A549 cells (a human lung cancer cell line not expressing CEA) (5 x 10
4
) were plated in 
V-bottomed microtiter plates in 100 µl RPMI-1640 containing 10% FCS (complete 
medium). Cells were incubated with 20 µg/ml of purified IgA, from the patient and HD, 
respectively for 30 min at room temperature followed by twice washing with RPMI1640. 
After washing, 20% normal human serum in complete medium was added to the cells and 
incubated at 37°C in humidified air with 5% CO2 for 1 h. Finally, cells were collected, 
washed twice with 1xPBS and resuspended in 100 µl of 1x binding buffer. Five µl of 
propidium iodine was added to the cells, vortexed and incubated at room temperature in the 
dark for 15 minutes. 100 µl of 1x binding buffer was added to the cells which were 
analyzed by flow cytometry. 
Results are presented as percent lysis (mean ± SEM), in four different groups; 1; cells 
alone, 2; cells incubated with human complement, 3; cells plus isolated IgA from the 
immunized patient +-human complement and 4; cells plus isolated IgA from HD ± human 
complement. Statistical calculations were done comparing groups by unpaired t-test. 
8.2.9 Antibody dependent cellular cytotoxicity (ADCC)  
ADCC was performed as previously described [236]. In brief, cell lines (same as used in 
CDC) were labeled with 2.8 MBq sodium 51Cr for 2 h. After 3 washings with DMEM 
medium 10000 cells in 100 µl medium were added to each round-bottomed microtiter well 
(Nunc) and Ficoll-isopaque isolated PBMC of healthy donors to yield target:effector cell 
ratios of 1:25 and 1:50 to a final volume of 200 µl. The test was run in sixplicate. After 24 
h at 37°C the reaction was stopped by centrifugation. 51Cr release was measured.  
The percentage of target cell lysis was calculated according to the following formula: 
% specific lysis = (experiment cpm-spontaneous cpm) / (maximal cpm-spontaneous cpm) x 
100. Maximal 51Cr release was determined by adding RIPA lysis buffer (150 mM NaCl, 25 
mM Tris PH=7, 5 mM EDTA, 0.5 % SDS and 1 % Triton X-100) to target cells and 
spontaneous release was measured in the absence of antibodies and effector cells (Paper I). 
In each cell line, results were compared between three groups; 1; Isolated IgA from 
immunized patient, 2; Isolated IgA from HD and 3; no antibody. Statistical calculations 
were done comparing groups by unpaired t-test. 
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8.3 Follow-up 
Paper I 
The first patient was included in Dec 1994 and the last in April 1996. Patients were 
contacted in July 2007 and their medical history was taken. Data was cross-checked with 
patient’s journals. Data on deceased patients were taken from patients journals. All patients 
were accounted for. Patients were monitored immunologically for 36 months and clinically 
for 154 months. 
 
Paper and II and III 
Systemic medical events occurring after the injection were assessed by the investigators 
and considered as product-related events only if their relation to the product was judged 
possible, probable or definite. AE were graded as to their seriousness, severity and 
relationship to the immunization by the investigators. NCI Common toxicity criteria 
(version 3.0) grades were applied (http://ctep.cancer.gov/reporting/ctc.html). Serious 
adverse events (SAEs) were defined as life threatening AE´s, or AE´s that resulted in 
significant or persistent disability, hospitalization, or death and were collected throughout 
the study period. 
Injection site and systemic symptoms were recorded in a memory aid up to the next 
scheduled visit. Patients were asked to measure erythema and oedema (only Paper II). 
Standard urine analysis and extensive laboratory tests were taken. 
The study period was 72 weeks during which the patients were monitored for safety, in 
total seven doctors visits. This was followed with clinical follow-up visits every 6 months, 
over a 5-year period, from the first immunization for long-term adverse events with special 
attention to autoimmune diseases, second malignancies, DFS and OS.  
 
Paper IV 
During the study, patients were regularly checked for performance status, routine blood 
haematology and chemistry analyses and serum tumour markers. AEs were assessed once 
weekly throughout the study period. 
AE were assessed according to the National Cancer Institute Common Toxicity 
Criteria versions 2.0 (Groups A/B) and 3.0 (Groups C/D) resp. and considered related to 
treatment if a relationship was reported as possible or probable. SAEs were defined as life 
threatening AE´s, or AE´s that resulted in significant or persistent disability, 
hospitalization, or death and were collected throughout the study period. 
8.4 Criteria for immune response 
Paper I 
ELISA: A patient was considered to have developed a significant response if IgM, IgA or 
IgE antibodies could be detected at at least two different time-points and was at least twice 
that of the pre-immunization value for that patient. 
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Paper III and IV 
 A patient was considered to have a single assay immune response if a response in one of 
the assays (proliferation, ELISPOT, Th-1 like cytokine secretion) was noted at one time 
point only against rCEA and/or CEA derived peptides (Paper III) or telomerase and/or 
ras (Paper IV). DTH was performed and included in overall induced immune response 
(OIIR) in Paper IV. Results of the ELISA assay were used descriptively (Paper IV). 
 A patient was considered to be an overall induced immune responder OIIR if a positive 
response (see above) was noted in at least one of the assays at at least at two time points. 
8.5 Statistical analysis 
Statistical analyses were done using Statview® (SAS Institute Inc. version 5.0 USA) 
(Papers I, II, III, IV) as well as IBM SPSS statistics (version 19) (Papers I, III). 
 
Paper I 
Comparison of pre-immunization anti-CEA titers of deceased and alive patients between 
groups were analysed by unpaired t-test. The relationship between survival and anti-CEA 
Ig-titers were analyzed by Cox-Regression analysis where the through mean values of IgM, 
IgA and IgE levels respectively for all patients at pre-immunization and at month 1, 2, 4, 
and 6 were calculated and listed from lowest to highest value. Patients with a through mean 
value below the median of all patients were labelled value 0. Patients with a mean value 
above the median of all patients were labelled value 1. This factor was analyzed in 
Wilcoxon Gehan exact test in relation to survival. As development of antibodies is “time 
dependant”, analysis of the prognostic impact of antibodies was performed after a fixed 
observation time [237]. As one patient died early, after 7 months, the 6 first months were 
used as observation time. The observation period and follow-up period were then held 
apart, avoiding “the pitfall of overlapping exposure and follow-up periods” [238]. Survival in 
relation to both anti-CEA IgA and anti-CEA IgG titers were also analysed. Patients were 
grouped according to those having both IgA and IgG anti-CEA antibody levels (through 
value) above the median (n=9) and the remaining patients (n=15). The relationship between 
anti-CEA IgA titers, GM-CSF and survival were analysed by Cox-regression analyses. The 
influence on survival by GM-CSF was assessed by univariate Wilcoxon Gehan exact life 
table test. 
 
Paper II 
Changes in size of erythema over time were analyzed using non-parametric tests (Friedman 
test and repeated measure ANOVA). Continuous parameters (differences in size between 
Cohort A and B) were compared by the Mann-Whitney U test. 
 
Paper III 
The non-parametric Friedman test for multiple comparisons was used to calculate relation 
of cell subsets at different time points. The Chi-square, Fisher test and one-way ANOVA 
tests were used to analyze differences in prognostic factors between groups and relation to 
immune responses. A p-value <0.05 was considered statistically significant. Life table 
landmark analysis with Wilcoxon Gehan exact test was used analyze a relationship 
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between OS as well as DFS to immune responses; landmark was set at 72 (part 1) and 52 
(part 2/3) weeks, i.e. close to the end of immunological evaluation. The landmark method 
for evaluating OS and DFS by immune response selects a fixed time, chosen by the 
investigator prior to the start of the study. Patients still on study at the landmark time are 
separated into two immune response categories (non-responders and responders) depending 
on immune response at the landmark time point. Patients were then followed onwards in 
time from the landmark [239, 240]. One way ANOVA and Friedmans test (non-parametric) 
were used to assess PPD and PHA differences at baseline between patients and healthy 
donors. 
 
Paper IV 
The non-parametric Mann Whitney two-tailed rank sum test for comparison of independent 
variables and the two-tailed non-parametric Wilcoxon signed rank test for dependent 
observations were applied. 
8.6 Ethics 
All studies were approved by the Regional Ethical Review Board in Stockholm. 
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9 RESULTS AND DISCUSSION 
9.1 Paper I 
Induction of IgM, IgA and IgE Antibodies in Colorectal Cancer patients vaccinated 
with Recombinant CEA protein. (J Clin Immuno. 32:855-856, 2012. Staff et al) 
 
Previous clinical studies have indicated that IgG antibodies have the ability to induce 
apoptosis of tumor cells but IgM, IgE and IgA may also mediate tumor cell killing [241-246]. 
The presence of spontaneously induced IgM anti-CEA antibodies has been associated with 
improved survival in CRC patients [247].However, there is scanty information on the Ig 
subclasses response after vaccination against cancer antigens. The clinical significance of 
the different Ig subclasses antibodies is not clear. 
In a previously reported study, twenty-four resected CRC patients without macroscopic 
disease were immunized seven times with the tumor associated protein rCEA ± GM-CSF 
[138, 248]. Four different dose schedules were used over a 12-month period. A significant anti-
rCEA-specific IgG1, IgG2 and IgG4 antibody response was shown and the induction of 
IgG correlated to improved survival.  
Hence, a follow-up study of patients previously enrolled in this vaccination study done 
by our group was carried out. The aim of this study, reported in Paper I, was to assess the 
induction of IgM, IgA and IgE anti-CEA antibodies, during 36 months after vaccination 
with rCEA with or without GM-CSF as an adjuvant. Isolated IgA from one vaccinated 
patient containing high IgA anti-CEA titers was tested in ADCC and CDC, using CEA 
positive and negative cell lines. Patients were evaluated for DFS and OS. The findings were 
correlated to DFS and OS. 
 
Most patients (83%) had a detectable IgM, a majority (54%) IgA and one patient had IgE 
anti-CEA antibodies before vaccination. Pre-immunization IgA, IgM and IgE anti-CEA 
titers did not differ significantly comparing deceased and alive patients. 
GM-CSF significantly augmented the anti-CEA response for all three antibody classes 
(p< 0.05). A strong IgM response was observed initially during vaccination with maximum 
titers at 3 months from start of vaccination. A rapid induction of IgA antibodies was noted 
already after one immunization, followed by gradual increase with a peak at 12 months. 
Repeated immunizations induced a gradual increase in the IgE anti-CEA antibody levels. 
Maximum IgE levels were noted at 15 months. The antibody curves over time (through 
values) in relation to GM-CSF were highly significant for IgM p=0.003; IgA p=0.006 and 
IgE p=0.007. The IgM-titers declined as expected much earlier than the IgA and IgE 
antibody levels. However, IgA and IgE anti-CEA levels clearly above pre-vaccination 
levels were still detectable 2 years after the last immunization. The dose of CEA had no 
significant effect on the IgM, IgA or IgE anti-CEA antibody responses.  
Six patients in the CEA alone group and six patients in the GM-CSF group relapsed 
and died during follow-up. Two further patients in the CEA alone group died from other 
causes than CRC. 
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A significant correlation between survival and high IgA anti-CEA titers was noted (p=0.02) 
irrespective of GM-CSF treatment. 
Anti-CEA IgA antibodies could significantly lyse CEA positive tumor cells in ADCC 
(p<0. 0001) as well as in CDC (p<0.0001). 
The addition of GM-CSF was practically mandatory to elict a vaccine induced IgM, 
IgA and IgE anti-CEA response as compared to patients receiving the vaccine alone. This 
finding corroborates our previous studies where GM-CSF was found to strongly enhance 
both the T cell and IgG responses [138, 248]. Fc receptors for IgA are found on 
monocytes/macrophages, polymorphonuclear neutrophils and NK-cells, i.e cells 
participating in ADCC [249]. In colon cancer patients elevated serum IgA immune 
complexes have been observed [241]. Moreover, IgA and IgG antitumor antibodies were 
shown to be equally effective in killing tumor cells in ADCC [241]. In conclusion, the 
observation that IgA anti-CEA antibodies were cytotoxic and associated with improved 
survival might indicate that also these antibodies may exert a clinical anti-tumor effect. 
Also, the duration of the humoral responses seen in Paper I, warrants further studies to 
evaluate rCEA as a therapeutic complement in patients with CRC. 
9.2 Paper II 
A phase I safety study of plasmid DNA immunization targeting carcinoembryonic 
antigen in colorectal cancer patients. (Vaccine. 29:6817-6822, 2011. Staff et al) 
 
The feasibility, safety and immunogenicity of therapeutic vaccination in CRC have been 
established. Different vaccination approaches targeting CEA in over 350 patients, including 
plasmid DNA as well as prime-boost vaccination strategies (74 patients) have only shown 
grade 2, and occasionally grade 3, toxicity [72, 138, 250-252]. 
In the present study, a plasmid DNA vaccine, encoding a truncated form of human 
CEA fused to a T-helper epitope (CEA66 DNA) was delivered three times i.d (2mg) or i.m 
(8mg), by a needle-free injector device, Biojector® to patients with colorectal cancer in the 
adjuvant setting. Five patients were included in each cohort (Cohorts A and B). Prior to the 
first vaccination, all patients received cyclophosphamide (300 mg/m2) intravenously (i.v). 
GM-CSF was administered s.c with each vaccination.  
Safety and tolerability were evaluated in all ten patients. All patients reported local 
injection site reactions but the majority was mild. 89% of the total local AE in Cohort A 
were grade 1; the corresponding figure for cohort B was 85% The frequency of patients 
with local grade 2 AEs increased during the 1st, 2nd and 3rd vaccinations and was 0%, 20% 
and 50% respectively in all patients. There was a significant increase in size of erythema at 
the injection sites from week 0 to week 6 in Cohort A, (p-value=0.015).  
Systemic AEs were also mild and transient (grade 1-2). There was a tendency that 
fatigue, headache and myalgia were more frequent in the i.d cohort. No grade 3 or 4 
adverse events possibly, probably or definitely associated with vaccination were reported. 
One SAE in one patient, in Cohort A, was not considered related to the study drugs. No 
signs of autoimmunity were seen. 
During follow-up time, one patient (Cohort A) died at week 99 due to urine bladder 
cancer, diagnosed 72 weeks after start of treatment. One patient (Cohort B) had disease 
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recurrence at week 52 and was alive at data collection. Eight out of ten patients have no 
evidence of disease. A concern for DNA vaccination is the integration into hosts cellular 
DNA that could result in mutagenesis. DNA vaccines currently in test do not show of 
integration into the host genome [253, 254]. In light of the short time period between the 
initiation of immunization in this study and diagnosis of the bladder cancer in two patients, 
as well as the coexistence of risk factors as smoking and previous pelvic radiotherapy, 
integration of CEA66 DNA could not have resulted in this new malignancy [255]. No signs 
of autoimmunity were seen. 
 
In conclusion, this phase I trial represents the first clinical trial on safety of a therapeutic 
vaccination strategy with plasmid DNA encoding human truncated CEA (CEA66 DNA), 
delivered by needle-free injection in combination with GM-CSF and cyclophosphamide in 
humans.  
Skin contains higher numbers of immunoreactive cells than muscle [90], which may 
explain the more frequent AE in the i.d cohort. The intradermal low dose DNA route 
indicated that skin may be a preferred site for immunization. Furthermore, the vaccine 
strategy was well tolerated, confirming the results of a preclinical mode [256]. 
9.3 Paper III 
Plasmid DNA immunization targeting carcinoembryonic antigen in colorectal 
cancer patients. (Manuscript, Staff et al) 
 
The method of DNA delivery as well as the localization of the expressed antigen can 
impact the outcome of DNA vaccination. The CEA66-DNA vaccine construct, evaluated in 
Paper II, encodes a modified, full-length, non-glycosylated form of CEA that is retained 
inside the cell. In preclinical studies, a T cell mediated response to CEA but weak antibody 
response was seen, using a needle-free pneumatic device (Biojector) [256, 257]. In contrast to 
the CEA66-DNA construct, DNA encoding wild type CEA (glycosylated) fused to a 
tetanus T-helper epitope (tetwtCEA-DNA), which is expressed as a membrane protein, 
induced a strong T cell as well as a antibody response [257].  
Delivery of DNA vaccine either i.m. or i.d by EP, may increase DNA uptake and 
antigen expression compared to needle injections [258, 259]. Short electrical pulses, at the site 
of vaccination, create transient pores in the cell membrane augmenting non-viral 
transfection of plasmid DNA. EP also causes a mild inflammation, with recruitment of 
APC at the site of injection without affecting persistence or integration of the plasmid [260, 
261]. 
In Paper III, we report immune data in an explorative study using CEA66-DNA and 
tetwt-CEADNA for immunization in combination with cyclophosphamide and GM-CSF in 
the adjuvant setting of CRC patients. Ten patients received i.d or i.m (cohorts I/II) CEA66-
DNA by Biojector (for details see Paper II) at weeks 0, 2 and 6 (part 1). Ten patients; 
cohorts III/IV (part 2), received tetwt-CEADNA 400µg i.d by needle followed by 
electroporation at weeks 0 and 12. Cohort V (part 3) (n=6) included patients primed with 
CEA66-DNA and boosted with tetwt-CEADNA. GM-CSF and cyclophosphamide was 
included in the vaccination schedules. 
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Adverse events regarding part 1 has previously been published [262] (Paper II), AEs 
regarding part 2 and 3 are shown in Table 8. The most frequently reported AEs were local 
injection site reactions, fatigue and nausea, but the majority was mild. No signs of 
autoimmunity were seen. 
 
Table 8. Frequency (%) of patients with AE treated with cyclophosphamide and vaccinated with 
tetwtCEA DNA without GM-CSF (part 2, cohort III; part 3, cohort V) and with GM-CSF (part 2, cohort 
IV) from baseline to week 24 (NCI Common toxicity criteria version 3.0 grades 1-3) a. 
Toxicity  Cohort III (n=5)  Cohort IV (n=5)  Cohort V (n=6)  Total (n=16) 
  G* 1-2 
No** (%) 
G 3 
No (%) 
 G 1-2 
No (%) 
G 3 
No (%) 
 G 1-2 
No (%) 
G 3 
No (%) 
 G 1-2 
No (%) 
G 3 
No (%) 
Local AE             
 Pain/discomfort  3 (60) 0 (0)  2 (40) 0 (0)  2 (33) 0 (0)  7 (44) 0 (0) 
 Erythema  1 (20) 0 (0)  4 (80) 0 (0)  2 (33) 0 (0)  7 (44) 0 (0) 
 Oedema  0 (0) 0 (0)  1 (20) 0 (0)  1 (17) 0 (0)  2 (13) 0 (0) 
 Warmth  0 (0) 0 (0)  0 (0) 0 (0)  0 (00) 0 (0)  0 (0) 0 (0) 
 Pruritus  2 (40) 0 (0)  1 (20) 0 (0)  5 (83) 0 (0)  8 (50) 0 (0) 
 Induration  0 (0) 0 (0)  0 (0) 0 (0)  0 (00) 0 (0)  0 (0) 0 (0) 
 
Systemic AE 
            
 Fatigue  2 (40) 1 (20)  2 (40) 0 (0)  4 (67) 0 (0)  8 (50) 1 (6) 
 Headache  1 (20) 0 (0)  1 (20) 0 (0)  0 (0) 0 (0)  2 (13) 0 (0) 
 Dizziness  1 (20) 0 (0)  2 (40) 0 (0)  0 (0) 0 (0)  3 (19) 0 (0) 
 Myalgia  1 (20) 0 (0)  0 (0) 0 (0)  1 (17) 0 (0)  2 (13) 0 (0) 
 Nausea  4 (80) 0 (0)  3 (60) 0 (0)  2 (33) 0 (0)  9 (56) 0 (0) 
 Anorexia  0 (0) 0 (0)  1 (20) 0 (0)  0 (0) 0 (0)  1 (6) 0 (0) 
 Arthralgia   0 (0) 0 (0)  1 (20) 0 (0)  1 (17) 0 (0)  2 (13) 0 (0) 
 Shivering  1 (20) 0 (0)  3 (60) 0 (0)  0 (0) 0 (0)  4 (25) 0 (0) 
 Swelling  0 (0) 0 (0)  0 (0) 0 (0)  0 (0) 1 (17)  0 (0) 1 (6) 
 Chest tightness  0 (0) 0 (0)  0 (0) 0 (0)  0 (0) 0 (0)  0 (0) 0 (0) 
 Diarrhoea  1 (20) 0 (0)  0 (0) 0 (0)  0 (0) 0 (0)  1 (6) 0 (0) 
 Pruritus general  0 (0) 0 (0)  0 (0) 0 (0)  0 (0) 1 (17)  0 (0) 1 (6) 
 Rash/urticaria  0 (0) 0 (0)  0 (0) 0 (0)  0 (0) 1 (17)  0 (0) 1 (6) 
 Microscopic 
 hematuria 
 0 (0) 0 (0)  0 (0) 0 (0)  1 (17) 0 (0)  1 (6) 0 (0) 
 
Metabolic 
            
 ALAT elevated  0 (0) 0 (0)  1 (20) 0 (0)  0 (0) 0 (0)  1 (6) 0 (0) 
 ASAT elevated   0 (0) 0 (0)  1 (20) 0 (0)  0 (0) 0 (0)  1 (6) 0 (0) 
a. No grade 4 AE was reported. *G=Grade. ** Represents the number of subjects experiencing adverse events. 
 
In total, 16 out of 20 (80%) patients mounted a single assay cellular response; 10/10 
(100%) in part 1 and in 6/10 (60%) of the patients in part 2. The difference between the 
CEA vaccine naïve patients was statistically significant (p = 0.025) in favour of part 1. 
OIIR was seen in 6/10 (60%) of the patients in part 1 and in 4/10 (40%) of the patients in 
part 2. The difference was statistically not significant.  
In part 3, 5/6 (83%) of the patients mounted a single response in one assay. In part 3 
OIIR was noted in 2/5 (40%) of the patients. All patients mounted a single assay cellular 
immune response in either part. In total, humoral responses were seen in two patients only. 
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(100%) in part 1 and in 6/10 ( 0%) of the patients in part 2. The difference b tw en th  
CEA vaccine naïv p tients was tatistically significant (p = 0.025) in favour of part 1. 
OIIR was seen in 6/10 (60%) of the patients in part 1 and in 4/10 (40%) of the patients in 
part 2. The difference was statistically not sig ificant.  
In part 3, 5/6 (83%) of the patients mounted a single respons  in one assay. In part 3 
OIIR was noted in 2/5 (40%) of the patients. All patients mounted a single assay cellular 
immune respons  in either part. In to al, humoral respons  wer  seen in two pa ients only. 
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There were no significant differences in either OS or DFS comparing single assay 
immune responders or OIIR in parts 1 and 2. 
 
In the present study, the frequency of patients mounting a single assay cellular immune 
response was significantly higher following Biojector delivery (part 1) compared to 
vaccination with electroporation in CEA vaccine naïve patients (part 2).  
An explanation might be a higher number of injections transfecting a larger number of 
cells and that Biojector delivery may evoke a substantial cell-trauma eliciting danger 
signals, enhancing an immune response induction [11, 12]. Immune responses are also higher 
when a higher dose of DNA plasmid is delivered [263]. Another explanation for a better 
immunogenicity in part 1 is the form of CEA-DNA used. The CEA-DNA construct used in 
part 1 generates a non-glycosylated protein that to a higher extent might be retained in the 
cytoplasm in comparison to the DNA construct used in part 2 yielding a glycosylated CEA 
protein which localizes to the plasma membrane. Thus, the CEA66-DNA might be more 
foreign compared to wild type CEA than the tetwtCEA-DNA used in part 2 [264, 265]. 
Likewise, in melanoma, a more heterogenous substance compared to the wild-type were 
more effective in breaking immune tolerance [266]. 
Mostly a Th-1 like cellular immune response was seen and only few individuals 
developed an antibody response, confirming the results in mice where CEA66-DNA 
primarily induced a cellular immune response[256]. Priming with CEA66-DNA and boosting 
with tetwtCEA-DNA did not augment the humoral response contradicting the results in 
mice by Brave et al [255]. Immune responses against CEA-derived peptides may suggest that 
CEA-DNA vaccination might induce both a CD4 and CD8 response. These results are 
supported by a preclinical study in mice vaccinated with CEA66-DNA, where a response 
against the B3 domain was mediated by CD4+ cells and towards the CTL-epitopes by 
CD8+ cells [256]. 
The results in Paper III indicate that self-tolerance against the tumor-associated antigen 
CEA could be broken, although weak but long-lasting. Similar to CEA66-DNA, tetwtCEA-
DNA, combined with cyclophosphamide and GM-CSF was safe [262].The present study also 
indicates that T cell responses could best be induced against CEA-DNA delivery by 
Biojector, which in this respect seemed to be superior to CEA-DNA injection followed by 
electroporation for immune induction. Extended studies are warranted to discriminate dose 
and delivery devices to determine the clinical significance of CEA-DNA vaccination in 
patients with CRC.  
9.4 Paper IV 
Telomerase-peptide vaccination (GV1001) together with gemcitabine in advanced 
pancreatic cancer patients. (Manuscript, Staff et al) 
 
In Paper IV, we assess safety and immunogenicity in non-resectable pancreatic cancer 
patients using a 16 aa telomerase peptide (GV1001) for vaccination in combination with 
GM-CSF and gemcitabine as first line treatment. 
Three different vaccine treatment schedules were used (A (n=6), B (n=6), C (n=5)). 
Groups A/B received GV1001, GM-CSF and gemcitabine concurrently. Group C received 
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initially GV1001 and GM-CSF while gemcitabine was added at disease progression. Group 
D (n=4) was treated with gemcitabine alone. 
 
AE related to vaccination were mild (grades 1-2). Grade 3 AEs were few and transient. A 
higher dose of GM-CSF induced a higher frequency and severity of injection site reactions. 
Gemcitabine related side-effects were as expected [267] and without overlapping toxicity 
with the vaccine treatment. One SAE was initially suspected to be related to GV1001 or 
GM-CSF in one patient in group C, who developed hepatic dysfunction (grade 3) due to 
liver metastasis. Both median time to progression and overall survival were most poor in 
group C. 
 
Four out of six (67%) patients developed a single assay immune response against 
telomerase and 3/6 (50%) against ras in group A. In group B, 4 out of 6 (67%) patients 
mounted a telomerase response and one (17%) against ras. A telomerase response in group 
C was noted in 2/5 (40%) patients and a ras response in 1/5 (20%) patients. In group D, a 
telomerase response was recorded in 2/4 (50%) patients and a ras response in 1/4 (25%) 
patients. 
OIIR was only seen in group A patients, in one patient against telomerase and in two 
patients against ras. The cytokine pattern was that of a Th1-profile. A significant decrease in 
regulatory T cells over time was noted in patients in groups A and B (p <0.05).  
 
The results might indicate that concomitant treatment with gemcitabine may not hamper 
the induction of an immune response but that delayed administration of gemcitabine might 
reduce the capacity to mount an immune response and favour tumor progression (group C). 
Telomerase vaccination (GV1001) in combination with chemotherapy appeared to be 
safe but the immune responses were weak and transient. Based on the experience of the 
present study and of those of others including immune responses and clinical efficacy, 
measures have to be taken to augment the magnitude and duration of the immune response 
to GV1001. Furthermore, advanced pancreatic carcinoma patients might not be a preferred 
clinical setting for vaccine treatment, as is the case for other tumors and tumor cancer 
vaccines [268]. Maybe the GV1001 vaccine is not an optimal telomerase vaccine candidate, 
although it has been shown that immune responders to GV1001 vaccination survived 
longer than non-immune responders [165] and CLL patients exhibited spontaneous T cells 
recognizing GV1001, which could lyse autologous telomerase expressing leukemic cells 
[153]. The study might also support the notion that multiple immune read-out systems might 
increase the sensitivity to detect antigen specific immune responses [269, 270]. 
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10 CONCLUSIONS AND FUTURE PERSPECTIVES 
Active immunotherapy is emerging as an important addition to conventional cancer 
treatments but many important questions remain. Effective strategies for overcoming 
immunosuppression need to be developed and patient selection are important. Optimal 
combinations of antigens, adjuvants and delivery vehicles need to be determined. 
Validation of surrogate endpoints and the identification of predictive biomarkers are 
equally important. 
 
A concept that is gaining acceptance in the field of active immunotherapy towards cancer is 
that vaccine monotherapy is unlikely to succeed in generating a robust and long-lasting 
memory. Synergism between existing chemotherapy and immunotherapy may lead to more 
clinical responses [271, 272]. Gemcitabine and 5-Fluorouracil have been implicated in the 
suppression of MDSC activity [273, 274]. Cyclophosphamide induced leucopenia results in an 
expansion of immature dendritic cells favouring immune responses [275] and may suppress 
Tregs [119, 276-279].  
The development of combination therapies is, however, associated with challenges. 
There is often little preclinical data on such combinations and phase I trials are required to 
show non-toxic combinations as well as to demonstrate immunological responses to the 
TCV. In Paper IV, gemcitabine combined with GV 1001 and GM-CSF did not seem to add 
to the toxicity but a decrease in the frequency of Tregs was seen. As shown in Paper II and 
III, the combination of cyclophosphamide and CEA-DNA vaccination was well tolerated 
with mild and transient side-effects. No significant decrease in the frequency of Tregs were 
seen, but the PHA responses increased in about 40% of the patients during vaccination, 
which might be due to reduced suppression induced by the cyclophosphamide treatment.  
 
Combinations of complementary immunotherapies may further induce sustained anti-tumor 
responses. By combining plasmid DNA vaccination with other modalities of antigen 
delivery, such as recombinant proteins, in heterologous prime/boost protocols, both B and 
T cell immune responses can be enhanced [280]. 
The results in Papers I and III combined, show a durable induction of anti-CEA 
antibodies following rCEA protein vaccination and long-lasting cellular responses 
following CEA-DNA vaccination. The induction of anti-CEA specific IgG antibodies as 
well as  proliferative T cell responses, following rCEA protein vaccination, has previously 
been published [138, 248]. In a preclinical study designed as a DNA prime/protein boost 
setting, cellular immune responses were of higher magnitude in animals primed with CEA-
DNA than in animals receiving repeated doses of rCEA protein [256]. In light of safety data 
presented in Paper II, a similar study would be feasible in humans. 
 
Clinical studies have demonstrated the ability of different TCV strategies to induce antigen-
specific T cells [281-284]. However, despite expanding antigen-specific T cells, in most 
clinical trials, tumors continue to grow [285-288]. Most clinical trials have been conducted in 
patients with advanced metastatic disease, and as tumors grow they evade immune 
destruction, for example by down-regulating HLA-expression [28, 289, 290]. In the present 
thesis, treatment with GV1001, GM-CSF and gemcitabine in patients with advanced 
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pancreatic cancer, mounted an immune response against telomerase in approximately two 
thirds of the patients in the best schedule. However, although the patients did not seem to 
be immune-hypo responsive as evaluated by PHA and PPD responses, immune response 
towards telomerase were weak and transient. In a number of clinical studies in which active 
immunotherapy failed to prolong survival, subgroup analyses suggested clinical benefit in 
patients with early or less aggressive disease [291-294]. 
 
For cell surface antigens, both CTL and humoral responses may mediate antitumor activity, 
attesting the importance of activating both CD8+ and CD4+ T cells [72]. Previous studies on 
rCEA protein vaccination in CRC patients resulted in both cellular and humoral CEA-
specific responses, and the IgG antibody responses to CEA correlated with increased 
survival [137, 138].  
Studies have suggested that IgM, IgA as well as IgE antibodies may have a role in 
eradicating cancer cells [241-246]. IgA antibodies have been proposed to be advantageous in 
tumor cell killing as compared to IgG [295]. In Paper I, rCEA vaccination combined with 
GM-CSF as an adjuvans, significantly induced durable antigen –specific humoral responses 
(IgA, IgM, IgE) against CEA and the induction of IgA was significantly correlated to 
survival. Furthermore, anti-CEA IgA could significantly lyse CEA positive cells. Most 
TCV studies focus on the induction of antigen-specific T cells. Future cancer vaccine trials 
might also assess the induction of the humoral response, including different isotypes. 
 
Modifications of the antigen may alter the immune response. In Paper III, the CEA-DNA 
construct used in part 1 generates a non-glycosylated protein that to a higher extent might 
be retained in the cytoplasm in comparison to the DNA construct used in part 2 yielding a 
glycosylated CEA protein which localizes to the plasma membrane. Tumor associated 
MUC1 is frequently hypoglycosylated on myeloma cells and this is associated by a more 
efficient antigen processing by dendritic cells, leading to stronger T cell responses [296-298]. 
DNA potency may also be improved by a) alteration to the plasmid itself to increase 
expression of immunogenicity (i.e. insertion of immune modulators) or b) placing DNA 
in/on microparticles acting as adjuvants for APCs [110].  
 
There is a need for development and validation of tools to identify patients who can benefit 
from a particular form of immunotherapy. Despite effort, we do not know which 
parameters of immune response, and which assays used to assess these parameters, are 
optimal for efficacy analysis. According to a workshop held 2011, involving FDA, 
National Cancer Institute and the International Society for Biological Therapy of Cancer-
Society for Immunotherapy of cancer (iSBTc-SITC), several key issues need to be 
addressed to identify patients and patient-groups who will benefit from treatment [299]. 
Recommendations included standardized handling of blood samples, use of robust and 
standardized assays. Furthermore, they recommend that several different assays used – to 
capture both the magnitude of the response, but also duration, quality and frequency. 
The characterization of responders and non-responders is difficult, assays yield plenty 
data. Distinguishing them from assay variation and normal human variation is difficult. 
Tight response criteria, requiring positive responses in 2 post-therapy time points is 
recommended [168]. Obtaining multiple pre-therapy samples, at different time-points, can be 
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used to assess pre-therapy variability and published raw data enables the reader to interpret 
data [168]. In addition, new analytes and/or biomarkers needs to be standardized and 
validated by other investigators before they are correlated to clinical outcome [168]. 
 
Looking ahead, an effective immune response that leads to an antitumor response requires 
not only an increase in immune activation but also reduction of suppressive immune 
checkpoints [278, 300]. The approval of mAb against CTLA-4 provided proof-of –principle for 
targeting immune suppressive checkpoints in the treatment of cancer [120] and mAb 
targeting PD1/PDL1 are in phase III clinical development. Synergy with TCV in mouse 
models suggests the potential for combining TCV with either of these mAbs [300-302].   
Moreover, the mechanisms whereby radiotherapy elicits tumor-specific immune 
responses have begun to emerge [303, 304]. Well designed trials are required to investigate this 
combotorial approach [305]. 
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